Clinical phenotype and molecular endotype features to select knee osteoarthritis patients for cell-based Anti-inflammatory therapy
By analyzing patient-reported outcomes and molecular endotype features, the method effectively stratifies knee osteoarthritis patients for cell-based anti-inflammatory treatments, enhancing treatment efficacy by identifying responsive phenotypes and endotypes.
Patent Information
- Application Number
- PCT/CA2024/050721
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-30
- Filing Date
- 2024-05-30
- Publication Date
- 2024-12-05
AI Technical Summary
Current treatments for knee osteoarthritis lack disease-modifying drugs, and cell-based anti-inflammatory therapies show variable responses due to the heterogeneous nature of the disease, making patient stratification challenging.
A method involving the determination of patient-reported outcome measures, local molecular endotype features from synovial fluid, and systemic molecular endotype features from serum/plasma/urine to identify responders versus non-responders to cell-based anti-inflammatory treatments, using biomarkers like HGF, VEGFA, CCL2, CTX-II, and CRP to select subjects for therapy.
This approach allows for the stratification of patients likely to respond to cell-based anti-inflammatory treatments, improving pain and function outcomes by identifying specific clinical phenotypes and molecular endotypes, thereby optimizing treatment efficacy.
Smart Images

Figure CA2024050721_05122024_PF_FP_ABST
Abstract
Description
CLINICAL PHENOTYPE AND MOLECULAR ENDOTYPE FEATURES TO SELECT KNEE OSTEOARTHRITIS PATIENTS FOR CELL-BASED ANTI-INFLAMMATORY THERAPYRelated Applications
[0001] This application claims the benefit of U.S. Provisional Patent Application 63 / 469,599 filed on May 30, 2023, herein incorporated by reference.Field
[0002] The present disclosure relates to methods for selecting a subject with knee osteoarthritis for a cell-based anti-inflammatory therapy or for treating said subject with a cell-based anti-inflammatory therapy.
[0003] Knee osteoarthritis (OA) is a complex and heterogeneous joint disease estimated to affect 16% of adults over 40 years of age worldwide [1], Pathophysiological mechanisms of OA are not fully understood, but include abnormal mechanical loading, metabolic, and inflammatory factors [2,3], Increasingly, the role of inflammation is recognized as a major contributing factor to OA symptomology and disease progression, with the joint synovium (consisting primarily of fibroblasts and macrophages) releasing pro-inflammatory factors that propagate the cartilage degradative cascade and contribute to patient symptoms [4,5], In particular, it has been shown that monocytes / macrophages (MOs, indicating a mixed population containing both monocytes and macrophages) represent the most abundant leukocyte population within the knee OA synovial fluid, and that levels of the CD14+CD16+(intermediate) MO subpopulation correlated to more severe patient-reported outcome measures (PROMs), indicating a key role of MO in OA disease pathology and symptomology [6],
[0004] Currently, there are no disease-modifying drugs available for OA, and patients rely on unsatisfactory symptom modification before resorting to total joint replacement at end stages of the disease [7], Culture-expanded mesenchymal stromal cells (MSCs), including those derived from bone marrow (MSC(M)), have emerged as a promising therapy for OA due to their multimodal mechanisms of action, which include chondroprotective / cartilage reparative, anti-fibrotic, and immunomodulatoryfunctions [8,9], Previously reported results of a first-in-Canada phase l / lla doseescalation clinical trial, showed improvements in patient pain, function, and other PROMs at 12 months relative to baseline in twelve patients administered with intraarticular autologous MSC(M) injections
[0010] , Several randomized controlled trials involving intra-articular injections of autologous [11-14] or allogeneic [15,16] MSC(M) have shown safety and preliminary efficacy in terms of PROM improvements relative to baseline and relevant control groups. However, variable responses have been documented in response to MSC injections, and effect sizes vary in terms of cartilage repair, pain, function, and other PROM improvements
[0017] ,
[0005] OA is a heterogeneous disease and numerous clinical phenotypes (referring to a patient’s clinical presentation of the disease) have been described based on factors such as pain sensitization, metabolic syndrome, mechanical loading, and joint alignment [18,19], Moreover, OA exhibits various molecular endotypes which refer to the profile of molecular drivers of the disease and may be characterized using local and / or systemic biomarkers
[0020] , Importantly, the relationships between clinical phenotype and molecular endotype are complex and can exhibit distinct or overlapping features, as well as temporal fluctuations [18,20], Given the vast heterogeneity of OA disease, new and improved methods of patient stratification for cell-based antiinflammatory therapies are desired.Summary
[0006] The present inventors have shown that responders to a cell-based antiinflammatory treatment for knee osteoarthritis exhibit distinct clinical phenotypes and molecular endotypes pre-treatment compared to non-responders to the treatment, which can be used to stratify a subject as a likely responder or non-responder to the cell-based anti-inflammatory treatment.
[0007] Accordingly, in an aspect, provided herein is a method of selecting a subject with knee osteoarthritis for a cell-based anti-inflammatory treatment comprising: a) determining a test profile comprising:i. a patient-reported outcome measure (PROM) score from an assessment of knee osteoarthritis and / or a physical activity assessment from the subject; ii. a local molecular endotype feature from a synovial fluid sample from the subject, wherein the local molecular endotype feature comprises expression profiles of hepatocyte growth factor (HGF), vascular endothelial growth factor A (VEGFA), and chemokine C-C motif ligand 2 (CCL2); and iii. a systemic molecular endotype feature from a sample of serum, plasma, and / or urine from the subject, wherein the systemic molecular endotype feature comprises expression profiles of C- telopeptide of type II collagen (CTX-II) and C-reactive protein (CRP); b) comparing the values of a) with a control profile comprising (i) the PROM score from the assessment of knee osteoarthritis and / or the physical activity assessment of known responders (KRs) or known non-responders (KNRs) to the cellbased anti-inflammatory treatment, (ii) the local molecular endotype feature from the synovial fluid sample of KRs or KNRs to the cell-based anti-inflammatory treatment, and (iii) the systemic molecular endotype feature from the sample of serum, plasma, and / or urine of KRs or KNRs to the cell-based anti-inflammatory treatment; c) determining the level of similarity of a) and b); and d) selecting the subject for the cell-based anti-inflammatory treatment if there is a high level of similarity of a) to KRs; and / or a low level of similarity of a) to KNRs, and not selecting the subject for the cell-based anti-inflammatory treatment if there is a low level of similarity of a) to KRs; and / or a high level of similarity of a) to KNRs.
[0008] Also provided herein, in an aspect, is a method of treating a subject with knee osteoarthritis with a cell-based anti-inflammatory treatment comprising: a) determining a test profile comprising: i. a patient-reported outcome measure (PROM) score from an assessment of knee osteoarthritis and / or a physical activity assessment from the subject;ii. a local molecular endotype feature from a synovial fluid sample from the subject, wherein the local molecular endotype feature comprises expression profiles of hepatocyte growth factor (HGF), vascular endothelial growth factor A (VEGFA), and chemokine C-C motif ligand 2 (CCL2); and iii. a systemic molecular endotype feature from a sample of serum, plasma, and / or urine from the subject, wherein the systemic molecular endotype feature comprises expression profiles of C- telopeptide of type II collagen (CTX-II) and C-reactive protein (CRP); b) comparing the values of a) with a control profile comprising (i) the PROM score from the assessment of knee osteoarthritis and / or the physical activity assessment of known responders (KRs) or known non-responders (KNRs) to the cellbased anti-inflammatory treatment, (ii) the local molecular endotype feature from the synovial fluid sample of KRs or KNRs to the cell-based anti-inflammatory treatment, and (iii) the systemic molecular endotype feature from the sample of serum, plasma, and / or urine of KRs or KNRs to the cell-based anti-inflammatory treatment; c) determining the level of similarity of a) and b); and d) administering the cell-based anti-inflammatory treatment if there is a high level of similarity of a) to KRs; and / or a low level of similarity of a) to KNRs, and not administering the cell-based anti-inflammatory treatment if there is a low level of similarity of a) to KRs; and / or a high level of similarity of a) to KNRs.
[0009] In an embodiment, the control profile of KRs or KNRs to the cell-based anti-inflammatory treatment is optionally first obtained by:I) determining a reference profile of one or more reference subjects with knee osteoarthritis pre cell-based anti-inflammatory treatment, comprising (i) the assessment of knee osteoarthritis and / or the physical activity assessment, (ii) the local molecular endotype feature from the synovial fluid sample from the reference subject, and (iii) the systemic molecular endotype feature from the sample of serum, plasma, and / or urine from the reference subject, wherein the local molecular endotype feature comprises expression profiles of HGF, VEGFA, and CCL2 and wherein the systemic molecular endotype feature comprises expression profiles of CTX-II and CRP;II) determining the assessment of knee osteoarthritis and / or the physical activity assessment of the reference subject post cell-based anti-inflammatory treatment;III) comparing the assessment of knee osteoarthritis and / or the physical activity assessment pre-treatment to the assessment of knee osteoarthritis and / or the physical activity assessment post-treatment in the reference subject;IV) assigning the reference subject to a KR group when the assessment of knee osteoarthritis and / or the physical activity assessment improved post-treatment compared to pre-treatment, and / or assigning the reference subject to a KNR group when the assessment of knee osteoarthritis and / or the physical activity assessment remained the same or worsened post-treatment compared to pre-treatment;V) obtaining the control profile of KRs from the reference profiles in the KR group and / or obtaining the control profile of KNRs from the reference profiles in the KNR group.
[0010] In an embodiment, the determining the assessment of knee osteoarthritis and / or the physical activity assessment of the reference subject post cellbased anti-inflammatory treatment in step II) is performed 3, 6, 12, or 24 months post cell-based anti-inflammatory treatment.
[0011] In another embodiment, the determining the assessment of knee osteoarthritis and / or the physical activity assessment of the reference subject post cellbased anti-inflammatory treatment in step II) is performed 12 or 24 months post cellbased anti-inflammatory treatment.
[0012] In an embodiment, determining the high level of similarity is indicated by a high correlation value computed between the test profile and the control profile, optionally wherein the correlation value is a correlation coefficient.
[0013] In an embodiment, determining the low level of similarity is indicated by a low correlation value computed between the test profile and the control profile, optionally wherein the correlation value is a correlation coefficient.
[0014] In an embodiment, the correlation coefficient is a linear coefficient, optionally a Pearson correlation coefficient, or a monotonic coefficient, optionally a Spearman’s correlation coefficient.
[0015] In some embodiments, the high level of similarity is indicated by a Pearson correlation coefficient or a Spearman’s correlation coefficient between the test profile and the control profile having an absolute value between 0.5 to 1 , optionally between 0.75 to 1 , and wherein the low level of similarity is indicated by a Pearson correlation coefficient or a Spearman’s correlation coefficient between the test profile and the control profile having an absolute value between 0 to 0.5, optionally between 0 to 0.25.
[0016] Also provided herein, in an aspect, is a method of treating knee osteoarthritis comprising administering a cell-based anti-inflammatory treatment to a subject that has been previously identified as having a responder profile, wherein the responder profile has been identified by determining a similarity of a) a test profile comprising (i) a patient-reported outcome measure (PROM) score from an assessment of knee osteoarthritis and / or a physical activity assessment, (ii) a local molecular endotype feature from a synovial fluid sample from the subject, wherein the local molecular endotype feature comprises expression profiles of hepatocyte growth factor (HGF), vascular endothelial growth factor A (VEGFA), and chemokine C-C motif ligand 2 (CCL2), and (iii) a systemic molecular endotype feature from a sample of serum, plasma, and / or urine from the subject, wherein the systemic molecular endotype feature comprises expression profiles of C-telopeptide of type II collagen (CTX-II) and C- reactive protein (CRP); and b) a control profile comprising (i) the PROM score from the assessment of knee osteoarthritis and / or a physical activity assessment of known responders (KRs) to the cell-based anti-inflammatory treatment, (ii) the local molecular endotype feature from the synovial fluid sample of KRs to the cell-based anti-inflammatory treatment, and (iii) the systemic molecular endotype feature from the sample of serum, plasma, and / or urine of KRs to the cell-based anti-inflammatory treatment.
[0017] Also provided herein, in an aspect, is use of a cell-based antiinflammatory treatment for treating knee osteoarthritis in a subject that has been previously identified as having a responder profile, wherein the responder profile has been identified by determining a similarity of a) a test profile comprising (i) a patient-reported outcome measure (PROM) score from an assessment of knee osteoarthritis and / or a physical activity assessment, (ii) a local molecular endotype feature from a synovial fluid sample from the subject, wherein the local molecular endotype feature comprises expression profiles of hepatocyte growth factor (HGF), vascular endothelial growth factor A (VEGFA), and chemokine C-C motif ligand 2 (CCL2), and (iii) a systemic molecular endotype feature from a sample of serum, plasma, and / or urine from the subject, wherein the systemic molecular endotype feature comprises expression profiles of C-telopeptide of type II collagen (CTX-II) and C- reactive protein (CRP); and b) a control profile comprising (i) the PROM score from the assessment of knee osteoarthritis and / or a physical activity assessment of known responders (KRs) to the cell-based anti-inflammatory treatment, (ii) the local molecular endotype feature from the synovial fluid sample of KRs to the cell-based anti-inflammatory treatment, and (iii) the systemic molecular endotype feature from the sample of serum, plasma, and / or urine of KRs to the cell-based anti-inflammatory treatment.
[0018] Also provided herein, in an aspect, is use of a cell-based antiinflammatory treatment in the manufacture of a medicament for treating knee osteoarthritis in a subject that has been previously identified as having a responder profile, wherein the responder profile has been identified by determining a similarity of a) a test profile comprising (i) a patient-reported outcome measure (PROM) score from an assessment of knee osteoarthritis and / or a physical activity assessment, (ii) a local molecular endotype feature from a synovial fluid sample from the subject, wherein the local molecular endotype feature comprises expression profiles of hepatocyte growthfactor (HGF), vascular endothelial growth factor A (VEGFA), and chemokine C-C motif ligand 2 (CCL2), and (iii) a systemic molecular endotype feature from a sample of serum, plasma, and / or urine from the subject, wherein the systemic molecular endotype feature comprises expression profiles of C-telopeptide of type II collagen (CTX-II) and C- reactive protein (CRP); and b) a control profile comprising (i) the PROM score from the assessment of knee osteoarthritis and / or a physical activity assessment of known responders (KRs) to the cell-based anti-inflammatory treatment, (ii) the local molecular endotype feature from the synovial fluid sample of KRs to the cell-based anti-inflammatory treatment, and (iii) the systemic molecular endotype feature from the sample of serum, plasma, and / or urine of KRs to the cell-based anti-inflammatory treatment.
[0019] In another aspect, provided herein is use of a cell-based antiinflammatory treatment for treating knee osteoarthritis in a subject that has been previously identified as having a responder profile by a method herein disclosed.
[0020] In another aspect, provided herein is use of a cell-based antiinflammatory treatment in the manufacture of a medicament for treating knee osteoarthritis in a subject that has been previously identified as having a responder profile by a method herein disclosed.
[0021] In yet another aspect, provided herein is a cell-based anti-inflammatory treatment for use in treating knee osteoarthritis in a subject that has been previously identified as having a responder profile, wherein the responder profile has been identified by determining a similarity of a) a test profile comprising (i) a patient-reported outcome measure (PROM) score from an assessment of knee osteoarthritis and / or a physical activity assessment, (ii) a local molecular endotype feature from a synovial fluid sample from the subject, wherein the local molecular endotype feature comprises expression profiles of hepatocyte growth factor (HGF), vascular endothelial growth factor A (VEGFA), and chemokine C-C motif ligand 2 (CCL2), and (iii) a systemic molecularendotype feature from a sample of serum, plasma, and / or urine from the subject, wherein the systemic molecular endotype feature comprises expression profiles of C-telopeptide of type II collagen (CTX-II) and C- reactive protein (CRP); and b) a control profile comprising (i) the PROM score from the assessment of knee osteoarthritis and / or a physical activity assessment of known responders (KRs) to the cell-based anti-inflammatory treatment, (ii) the local molecular endotype feature from the synovial fluid sample of KRs to the cell-based anti-inflammatory treatment, and (iii) the systemic molecular endotype feature from the sample of serum, plasma, and / or urine of KRs to the cell-based anti-inflammatory treatment.
[0022] In a further aspect, provided herein is a cell-based anti-inflammatory treatment for use in treating knee osteoarthritis in a subject that has been previously identified as having a responder profile by a method herein disclosed.
[0023] In another embodiment, the expression profile of CTX-II is from urine and / or the expression profile of CRP is from serum.
[0024] In some embodiments, the systemic molecular endotype feature further comprises an expression profile of interleukin 6 (IL-6) and / or cartilage oligomeric matrix protein (COMP).
[0025] In an embodiment, the expression profile of IL-6 and / or COMP is from plasma.
[0026] In an embodiment, the local molecular endotype feature further comprises an expression profile of resistin and / or TIMP metallopeptidase inhibitor 1 (TIMP1), and / or wherein the systemic molecular endotype feature further comprises an expression profile of tumor necrosis factor alpha (TNFa) and / or C1 -2C collagen type I and II cleavage (C1-2C).
[0027] In another embodiment, the expression profile of TNFa is from plasma and / or the expression profile of C1-2C is from serum.
[0028] In yet another embodiment, the local molecular endotype feature further comprises an expression profile of soluble CD163 (sCD163), and / or wherein thesystemic molecular endotype feature further comprises S100A8 / A9 heterodimer (S100A8 / A9).
[0029] In an embodiment, the expression profile of S100A8 / A9 is from serum.
[0030] In another embodiment, the local molecular endotype feature further comprises an expression profile of adipsin and / or matrix metalloproteinase 13 (MMP- 13).
[0031] In some embodiments, the cell-based anti-inflammatory treatment comprises mesenchymal stromal or stem cells, bone marrow aspirate, bone marrow aspirate concentrate, autologous fat transfer, concentrated adipose tissue, stromal vascular fraction, platelet-rich plasma, particulate or tissue derived from the placenta and / or amniotic membrane, autologous protein solution, or autologous conditioned serum.
[0032] In an embodiment, the cell-based anti-inflammatory treatment comprises the mesenchymal stromal cells.
[0033] In another embodiment, the synovial fluid sample and / or the sample of serum, plasma, and / or urine was obtained between one month prior to and immediately prior to the cell-based anti-inflammatory treatment.
[0034] In an embodiment, the subject is a human subject.
[0035] In some embodiments, the subject has not received a previous treatment for knee osteoarthritis.
[0036] In other embodiments, the subject has previously received at least one treatment for knee osteoarthritis.
[0037] In some embodiment, the assessment of knee osteoarthritis comprises Knee injury and Osteoarthritis Outcome Score (KOOS), Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), Visual Analogue Scale (VAS), Short Form 36 (SF-36) or Short Form 12 (SF-12), Tegner Lysholm Knee Score, Knee Society Clinical Rating System, Lequesne Index for Knee Osteoarthritis, Oxford Knee Score (OKS) and / or International Knee Documentation Committee (IKDC) Questionnaire.
[0038] In an embodiment, when the assessment of knee osteoarthritis comprises KOOS, the PROM score comprises Function in Sports and Recreation (Sports / Rec) and / or Overall KOOS.
[0039] In another embodiment, when the assessment of knee osteoarthritis comprises WOMAC, the PROM score comprises Overall WOMAC.
[0040] In yet another embodiment, the physical activity assessment comprises Marx Activity Rating Scale (MARS), SF36 Physical Function Score, International Physical Activity Questionnaire (IPAQ), Timed Up and Go Test (TUG), and / or 6 Minute Walk Test.
[0041] Other features and advantages of the present disclosure will become apparent from the following detailed description. It should be understood, however, that the detailed description and specific examples, while indicating embodiments of disclosure, are given by way of illustration only, and the scope of the claims should not be limited by these embodiments but should be given the broadest interpretation consistent with the description as a whole.Brief Description of the Drawings
[0042] For a better understanding of the various embodiments described herein, and to show more clearly how these various embodiments may be carried into effect, reference will be made, by way of example, to the accompanying drawings which show at least one example embodiment, and which are now described. The drawings are not intended to limit the scope of the teachings described herein.
[0043] Fig. 1 shows a graphical abstract of the experimental design in an exemplary embodiment of the disclosure.
[0044] Fig. 2 shows that osteoarthritis patient responders demonstrate improvements in Knee injury and Osteoarthritis Outcome Score (KOOS) subscales that are maintained out to 24 months follow-up post-injection in an exemplary embodiment of the disclosure. Patients categorized as Function-Pain Responders displayed significant improvements (indicated by lower score values) in all KOOS subscales and overall KOOS at 12- and 24-months follow-up relative to baseline, while non-responders displayed no significant changes. KOOS scales were inverted suchthat higher scores represent greater knee-related issues. N=12 patients. Two-way repeated measures ANOVA, Dunnett’s multiple comparisons test. *p<0.05, **p<0.01 , ***p<0.001 , ****p<0.0001 ; asterisks indicate significant differences for responder group relative to baseline at the time points indicated. ADL: function in daily living; Sports / Rec: function in sport and recreation; QOL: knee-related quality of life; KOOS: Knee injury and Osteoarthritis Outcome Score. Function-Pain Responders are represented by circles, and Non-Responders are represented by squares.
[0045] Fig. 3A shows that osteoarthritis patient function-responders demonstrate improvements in KOOS outcomes that are maintained out to 24 months follow-up post-injection in an exemplary embodiment of the disclosure. Patients categorized as Function Responders displayed significant improvements in KOOS subscales and overall KOOS at 12- and 24-months follow-up relative to baseline, while non-responders displayed no significant changes. N=12 patients. KOOS scales were inverted such that higher scores represent greater knee-related issues. Two-way repeated measures ANOVA, Dunnett’s multiple comparisons test. *p<0.05, **p<0.01 , ***p<0.001 , ****p<0.0001 ; asterisks indicate significant differences for responder group relative to baseline at the time points indicated. ADL: function in daily living; Sports / Rec: function in sport and recreation; QOL: knee-related quality of life; KOOS: Knee injury and Osteoarthritis Outcome Score. Function responders are represented by circles, and Non-Responders are represented by squares.
[0046] Fig. 3B shows that osteoarthritis patient pain-responders demonstrate improvements in KOOS outcomes that are maintained out to 24 months follow-up post-injection in an exemplary embodiment of the disclosure. Patients categorized as Pain Responders displayed significant improvements in KOOS subscales and overall KOOS at 12- and 24-months follow-up relative to baseline, while non-responders displayed no significant changes. N=12 patients. KOOS scales were inverted such that higher scores represent greater knee-related issues. Two-way repeated measures ANOVA, Dunnett’s multiple comparisons test. *p<0.05, **p<0.01 , ***p<0.001 , ****p<0.0001 ; asterisks indicate significant differences for responder group relative to baseline at the time points indicated. ADL: function in daily living; Sports / Rec: function in sport and recreation; QOL: knee-related quality of life; KOOS:Knee injury and Osteoarthritis Outcome Score. Pain Responders are represented by circles, and Non-Responders are represented by squares.
[0047] Fig. 4A shows that patients categorized according to Pain-Function Responders and Non-responders displayed no significant differences between overall KOOS and KOOS subscales at baseline in an exemplary embodiment of the disclosure. Pain-Function responders are represented by circles, and non-responders are represented by squares. Horizontal lines: group mean; error bars: standard deviation. N=12 patients.
[0048] Fig. 4B shows that patients categorized according to Function Responders displayed significantly more severe overall KOOS and Sports / Rec scores at baseline relative to Non-Responders in an exemplary embodiment of the disclosure. Function responders are represented by circles, and non-responders are represented by squares. Student’s t-test (for baseline Overall KOOS), Two-way ANOVA, Sidak’s post-hoc test (for baseline KOOS Subscales), *p<0.05, **p<0.01. n.s.; non-significant. N=12 patients. ADL: function in daily living; Sports / Rec: function in sport and recreation; QOL: knee-related quality of life. Horizontal lines: group mean; error bars: standard deviation.
[0049] Fig. 4C shows significant correlations between baseline KOOS Sports / Rec scores and improvements at 12 months and 24 months relative to baseline in an exemplary embodiment of the disclosure. Top left shows improvements in delta function in daily living (ADL) scores at 12 months relative to baseline (rs = 0.6056; p=0.0369). Top right shows improvements in delta ADL scores at 24 months relative to baseline (rs = 0.5845; p=0.0459). Bottom left shows percentage change in symptoms at 24 months relative to baseline (rs = 0.6081 ; p=0.0359). Bottom right shows delta overall KOOS at 24 months relative to baseline (rs = 0.6018; p=0.0384). KOOS scales were inverted such that higher scores represent greater knee-related issues; delta and percent change in KOOS values were made relative to baseline and calculated such that positive values represent improvement. N=12 patients. Spearman’s correlation.
[0050] Fig. 4D shows significant negative correlations between baseline MARS scores and baseline KOOS Sports / Rec Scores or change in KOOS Pain or SymptomScores at 12 months relative to baseline in an exemplary embodiment of the disclosure. Top left shows that higher MARS scores (more frequent physical activity) are correlated with lower (less severe) KOOS Sports / Rec scores at baseline (rs = - 0.6322; p=0.0274). Top right shows that higher baseline MARS scores are negatively correlated with percentage change in symptoms at 12 months relative to baseline (rs = -0.5897; p=0.0436). Bottom left shows that higher baseline MARS scores are negatively correlated with delta pain change at 12 months relative to baseline (rs = - 0.7777; p=0.0029). Bottom right shows that higher baseline MARS scores are negatively correlated with percentage change in symptoms at 12 months relative to baseline (rs = -0.7502; p=0.0049). N=12 patients. Spearman’s correlation.
[0051] FIG. 5 shows that patients categorized as Pain Responders displayed no significant differences in overall KOOS or subscales relative to non-responders at baseline in an exemplary embodiment of the disclosure. KOOS scales were inverted such that higher scores represent greater knee-related issues. N=12 patients. Student’s t-test (for baseline Overall KOOS; top), two-way ANOVA, Sidak’s post-hoc test (for baseline KOOS Subscales; bottom), n.s.: non-significant; ADL: function in daily living; Sports / Rec: function in sport and recreation; QOL: knee-related quality of life; KOOS: Knee injury and Osteoarthritis Outcome Score. Horizontal lines: group mean; error bars: standard deviation. Pain Responders are represented by circles, and Non-Responders are represented by squares.
[0052] FIG. 6A shows that local synovial fluid biomarkers measured at baseline correlate to patient-reported outcome measures at 24 months relative to baseline in an exemplary embodiment of the disclosure. Top left shows that higher levels of resistin significantly positively correlate to delta values in KOOS Sports / Rec scores at 24 months (rs =0.7236; p=0.0276). Top right shows that higher levels of TIMP1 significantly correlate inversely to the percentage change in KOOS Sports / Rec scores at 24 months relative to baseline (rs = -0.7306; p=0.0396). Bottom left shows that higher levels of CCL2 significantly correlate inversely to delta change in KOOS Sports / Rec scores at 24 months relative to baseline (rs = -0.7229; p=0.0427). Bottom right shows that higher levels of CCL2 significantly correlate inversely to percentage change in KOOS Sports / Rec scores at 24 months relative to baseline (rs = -0.8503; p=0.0075). N=8-9 patients. Spearman’s correlation. Sports / Rec: function in sport andrecreation; MO: month; KOOS: Knee injury and Osteoarthritis Outcome Score; TIMP1 : tissue inhibitor of metalloproteinases 1 ; CCL2: chemokine C-C motif ligand 2.
[0053] Fig. 6B shows that local synovial fluid biomarkers measured at baseline correlate to patient-reported outcome measures at 12 months relative to baseline in an exemplary embodiment of the disclosure. Higher levels of HGF in synovial fluid significantly correlate inversely to delta values (left; rs = -0.7857; p=0.0208) and / or percentage change (middle; rs = -0.7143; p=0.0465) in KOOS Pain scores at 12 months relative to baseline. Right shows that higher levels of VEGFA in synovial fluid significantly correlate inversely to percentage change in in KOOS pain scores at 12 months relative to baseline (rs = -0.8095; p=0.0149). Delta and percent change in KOOS values were made relative to baseline and calculated such that positive values represent improvement. N=8-9 patients. Spearman’s correlation. MO: month; KOOS: Knee injury and Osteoarthritis Outcome Score; HGF: hepatocyte growth factor; VEGFA: vascular endothelial growth factor A.
[0054] Fig. 6C shows that local synovial fluid biomarkers measured at baseline correlate to patient-reported outcome measures at 3 months relative to baseline in an exemplary embodiment of the disclosure. Top shows that higher levels of sCD14 significantly correlate inversely to the delta in KOOS Symptom (left; rs = -0.7306; p=0.0396) the percentage change in KOOS Symptom (middle; rs = -0.7619; p=0.028) and percentage change in Sports / Rec (right; rs = -0.7425; p=0.0349) scores at 3 months relative to baseline. Bottom shows that CCL2 significantly correlate inversely to the delta in KOOS Symptom (left; rs = -0.8982; p=0.0024) the percentage change in KOOS Symptom (middle; rs = -0.9048; p=0.0020) and percentage change in Sports / Rec (right; rs = -0.8383; p=0.0093) scores at 3 months relative to baseline. Delta and percent change in KOOS values were made relative to baseline and calculated such that positive values represent improvement. N=8-9 patients. Spearman’s correlation. Sports / Rec: function in sport and recreation; MO: month; KOOS: Knee injury and Osteoarthritis Outcome Score; CCL2: chemokine C-C motif ligand 2; sCD14: soluble CD14.
[0055] Fig. 7A shows that Levels of CD14+CD16+ (intermediate monocyte / macrophages, MO) trended lower in Function-Pain Responders than inNon-Responders in an exemplary embodiment of the disclosure. N=5 synovial fluid samples. Horizontal lines: group means.
[0056] Fig. 7B shows that there was a trend for higher levels of CD14+CD16neg (classical MO) in Function-Pain Responders than in Non-Responders in an exemplary embodiment of the disclosure. . N=5 synovial fluid samples. Horizontal lines: group means.
[0057] Fig, 7C shows that levels of CD14+CD163+ MO trended lower in Function-Pain Responders versus Non-Responders in an exemplary embodiment of the disclosure. N=5 synovial fluid samples. Horizontal lines: group mean.
[0058] Fig. 8A shows that higher levels of TNFa measured in plasma at baseline significantly positively correlated to percentage change in KOOS Pain (top; rs = 0.6713; p=0.0168) and QOL (bottom; rs = 0.5944; p=0.0415) at 6 months relative to baseline in an exemplary embodiment of the disclosure. Delta and percent change in KOOS values were made relative to baseline and calculated such that positive values represent improvement. N=12 patients. Spearman’s correlation. MO: month; KOOS: Knee injury and Osteoarthritis Outcome Score; TNFa: tumour necrosis factor-alpha.
[0059] Fig. 8B shows that higher levels of S100A8 / A9 measured in serum at baseline correlate inversely to percentage change (top; rs = -0.6585; p=0.0199) and delta values (middle; rs = -0.6432; p=0.0240) for KOOS QOL, and percentage change in KOOS Sports / Rec (bottom; rs = -0.6526; p=0.0214) at 3 months relative to baseline in an exemplary embodiment of the disclosure. Delta and percent change in KOOS values were made relative to baseline and calculated such that positive values represent improvement. N=12 patients. Spearman’s correlation. Sports / Rec: function in sport and recreation; MO: month; KOOS: Knee injury and Osteoarthritis Outcome Score.
[0060] Fig. 9A shows that patients categorized according to Pain-Function Responders and Non-responders displayed no significant differences between overall WOMAC (left) and WOMAC subscales (right) at baseline in an exemplary embodiment of the disclosure. N=12 patients. Horizontal lines: group mean; error bars: standard deviation. Student’s t-test (for baseline Overall WOMAC), Two-way ANOVA, Sidak’s post-hoc test (for baseline WOMAC Subscales). WOMAC: Western Ontario andMcMaster Universities Osteoarthritis Index. Pain-Function responders are represented by circles, and non-responders are represented by squares.
[0061] Fig. 9B shows that patients categorized as Function Responders displayed significantly more severe overall WOMAC scores (left) and no significant differences in WOMAC subscales (right) at baseline relative to Non-Responders in an exemplary embodiment of the disclosure. N=12 patients. Horizontal lines: group mean; error bars: standard deviation. Student’s t-test (for baseline Overall WOMAC), Two- way ANOVA, Sidak’s post-hoc test (for baseline WOMAC Subscales). *p<0.05. Function responders are represented by circles, and non-responders are represented by squares.
[0062] Fig. 9C shows that patients categorized according to Pain Responders and Non-responders displayed no significant differences between overall WOMAC and WOMAC subscales at baseline. N=12 patients. Horizontal lines: group mean; error bars: standard deviation. Student’s t-test (for baseline Overall WOMAC), Two- way ANOVA, Sidak’s post-hoc test (for baseline WOMAC Subscales). Pain responders are represented by circles, and non-responders are represented by squares.
[0063] Further aspects and features of the example embodiments described herein will appear from the following description taken together with the accompanying drawings.Detailed Description of the Disclosure
[0064] The following is a detailed description provided to aid those skilled in the art in practicing the present disclosure. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. The terminology used in the description herein is for describing particular embodiments only and is not intended to be limiting of the disclosure. All publications, patent applications, patents, figures and other references mentioned herein are expressly incorporated by reference in their entirety.
[0065] Further, the definitions and embodiments described in particular sections are intended to be applicable to other embodiments herein described forwhich they are suitable as would be understood by a person skilled in the art. For example, in the following passages, different aspects of the disclosure are defined in more detail. Each aspect so defined may be combined with any other aspect or aspects unless clearly indicated to the contrary. In particular, any feature described herein may be combined with any other feature or features described herein, except combinations where at least some of such features and / or steps are mutually exclusive.I. Definitions
[0066] As used herein, the following terms may have meanings ascribed to them below, unless specified otherwise. However, it should be understood that other meanings that are known or understood by those having ordinary skill in the art are also possible, and within the scope of the present disclosure. In the case of conflict, the present specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting.
[0067] In understanding the scope of the present disclosure, the term "comprising" and its derivatives, as used herein, are intended to be open ended terms that specify the presence of the stated features, elements, components, groups, integers, and / or steps, but do not exclude the presence of other unstated features, elements, components, groups, integers and / or steps. The foregoing also applies to words having similar meanings such as the terms, "including", "having" and their derivatives.
[0068] The term “consisting” and its derivatives, as used herein, are intended to be closed ended terms that specify the presence of stated features, elements, components, groups, integers, and / or steps, and also exclude the presence of other unstated features, elements, components, groups, integers and / or steps. The term “consisting essentially of”, as used herein, is intended to specify the presence of the stated features, elements, components, groups, integers, and / or steps as well as those that do not materially affect the basic and novel characteristic(s) of features, elements, components, groups, integers, and / or steps.
[0069] Further, terms of degree such as "substantially", "about" and "approximately" as used herein mean a reasonable amount of deviation of themodified term such that the end result is not significantly changed. These terms of degree should be construed as including a deviation of at least ±5% of the modified term if this deviation would not negate the meaning of the word it modifies.
[0070] As used in this specification and the appended claims, the singularforms “a”, “an” and “the” include plural references unless the content clearly dictates otherwise. Thus, for example, a composition containing “a compound” includes a mixture of two or more compounds.
[0071] The phrase "and / or," as used herein in the specification and in the claims, should be understood to mean "either or both" of the elements so conjoined, i.e., elements that are conjunctively present in some cases and disjunctively present in other cases. Multiple elements listed with "and / or" should be construed in the same fashion, i.e., "one or more" of the elements so conjoined. Other elements may optionally be present other than the elements specifically identified by the "and / or" clause, whether related or unrelated to those elements specifically identified.
[0072] As used herein, "or" should be understood to have the same meaning as "and / or" as defined above. For example, when separating items in a list, "or" or "and / or" shall be interpreted as being inclusive, i.e., the inclusion of at least one, but also including more than one, of a number or list of elements, and, optionally, additional unlisted items. Only terms clearly indicated to the contrary, such as "only one of or "exactly one of" or, when used in the claims, "consisting of" will refer to the inclusion of exactly one element of a number or list of elements. In general, the term "or" as used herein shall only be interpreted as indicating exclusive alternatives (i.e., "one or the other but not both") when preceded by terms of exclusivity, such as "either," "one of," "only one of," or "exactly one of."
[0073] As used herein, the phrase "at least one," in reference to a list of one or more elements, should be understood to mean at least one element selected from anyone or more of the elements in the list of elements, but not necessarily including at least one of each and every element specifically listed within the list of elements and not excluding any combinations of elements in the list of elements. This definition also allows that elements may optionally be present other than the elementsspecifically identified within the list of elements to which the phrase "at least one" refers, whether related or unrelated to those elements specifically identified.
[0074] The recitation of numerical ranges by endpoints herein includes all numbers and fractions subsumed within that range (e.g. 1 to 5 includes 1 , 1.5, 2, 2.75, 3, 3.90, 4, and 5). It is also to be understood that all numbers and fractions thereof are presumed to be modified by the term "about."
[0075] It should also be understood that, in certain methods described herein that include more than one step or act, the order of the steps or acts of the method is not necessarily limited to the order in which the steps or acts of the method are recited unless the context indicates otherwise.
[0076] It will be understood that any component defined herein as being included can be explicitly excluded by way of proviso or negative limitation, such as any specific compounds or method steps, whether implicitly or explicitly defined herein.
[0077] Although any methods and materials similar or equivalent to those described herein can also be used in the practice or testing of the present disclosure, examples of methods and materials are now described.II. Methods and Uses
[0078] The present inventors have shown that responders to a cell-based antiinflammatory treatment for knee osteoarthritis exhibit distinct clinical phenotypes and molecular endotypes pre-treatment compared to non-responders to the treatment, which can be used to stratify a subject as a likely responder or non-responder to the cell-based anti-inflammatory treatment.
[0079] Accordingly, in one aspect, the present disclosure provides a method of selecting a subject with knee osteoarthritis for a cell-based anti-inflammatory treatment comprising: a) determining a test profile comprising: i. a patient-reported outcome measure (PROM) score from an assessment of knee osteoarthritis and / or a physical activity assessment from the subject;ii. a local molecular endotype feature from a synovial fluid sample from the subject, wherein the local molecular endotype feature comprises expression profiles of hepatocyte growth factor (HGF), vascular endothelial growth factor A (VEGFA), and chemokine C-C motif ligand 2 (CCL2); and iii. a systemic molecular endotype feature from a sample of serum, plasma, and / or urine from the subject, wherein the systemic molecular endotype feature comprises expression profiles of C- telopeptide of type II collagen (CTX-II) and C-reactive protein (CRP); b) comparing the values of a) with a control profile comprising (i) the PROM score from the assessment of knee osteoarthritis and / or the physical activity assessment of known responders (KRs) or known non-responders (KNRs) to the cellbased anti-inflammatory treatment, (ii) the local molecular endotype feature from the synovial fluid sample of KRs or KNRs to the cell-based anti-inflammatory treatment, and (iii) the systemic molecular endotype feature from the sample of serum, plasma, and / or urine of KRs or KNRs to the cell-based anti-inflammatory treatment; c) determining the level of similarity of a) and b); and d) selecting the subject for the cell-based anti-inflammatory treatment if there is a high level of similarity of a) to KRs; and / or a low level of similarity of a) to KNRs, and not selecting the subject for the cell-based anti-inflammatory treatment if there is a low level of similarity of a) to KRs; and / or a high level of similarity of a) to KNRs.
[0080] In another aspect, the present disclosure provides a method of treating a subject with knee osteoarthritis with a cell-based anti-inflammatory treatment comprising: a) determining a test profile comprising: i. a patient-reported outcome measure (PROM) score from an assessment of knee osteoarthritis and / or a physical activity assessment from the subject; ii. a local molecular endotype feature from a synovial fluid sample from the subject, wherein the local molecular endotype feature comprises expression profiles of hepatocyte growth factor (HGF), vascularendothelial growth factor A (VEGFA), and chemokine C-C motif ligand 2 (CCL2); and iii. a systemic molecular endotype feature from a sample of serum, plasma, and / or urine from the subject, wherein the systemic molecular endotype feature comprises expression profiles of C- telopeptide of type II collagen (CTX-II) and C-reactive protein (CRP); b) comparing the values of a) with a control profile comprising (i) the PROM score from the assessment of knee osteoarthritis and / or the physical activity assessment of known responders (KRs) or known non-responders (KNRs) to the cellbased anti-inflammatory treatment, (ii) the local molecular endotype feature from the synovial fluid sample of KRs or KNRs to the cell-based anti-inflammatory treatment, and (iii) the systemic molecular endotype feature from the sample of serum, plasma, and / or urine of KRs or KNRs to the cell-based anti-inflammatory treatment; c) determining the level of similarity of a) and b); and d) administering the cell-based anti-inflammatory treatment if there is a high level of similarity of a) to KRs; and / or a low level of similarity of a) to KNRs, and not administering the cell-based anti-inflammatory treatment if there is a low level of similarity of a) to KRs; and / or a high level of similarity of a) to KNRs.
[0081] The term “subject” as used herein refers to a mammal, for example a human, a domesticated animal, or livestock. A domesticated animal can, for example, be a canine, an equine, or a feline. In an embodiment, the subject is a human subject. In another embodiment, the subject is canine, equine, or feline.
[0082] The term “osteoarthritis” as used herein refers to a degenerative joint disease, causing breakdown of the articular cartilage accompanied by symptoms such as pain, stiffness, and disability. Accordingly, “knee osteoarthritis” refers to osteoarthritis of the knee joint and can be characterized by radiographic changes to the cartilage and other tissues in this joint.
[0083] The term “patient-reported outcome measure score” or “PROM score” as used herein refers to any patient-reported symptomatic variable associated with a clinical phenotype of knee osteoarthritis. A PROM score can, for example, be derived from an assessment of knee osteoarthritis and / or a physical activity assessment. The PROM score may, for example, be an absolute, relative, interval, or ordinal value.
[0084] The term “synovial fluid” or “synovia” as used herein means a viscous fluid found in the cavities of the knee joint.
[0085] The term “molecular endotype” as used herein means a classification of osteoarthritic pathogenesis at the molecular and / or cellular level, without regard to its clinical presentations. An endotype is often used to describe a subtype of a disease or condition, which is defined by a distinct functional or pathobiological mechanism. Endotype implies the presence of a well-defined molecular mechanism and is distinct from clinical phenotypes. Molecular endotypes can be defined by specific cells and / or biomarker molecules in blood, urine, synovial fluid, saliva or other body fluids. Accordingly, the term “molecular endotype feature” as used herein means any measure of a variable that contributes to the molecular endotype or that is indicative of the molecular endotype, for example absolute or relative biomarker expression levels or changes in biomarker expression levels. Relevant biomarkers can include, for example, local or systemic inflammatory, angiogenic, metabolic, or cartilage extracellular matrix-associated biomarkers.
[0086] HGF can be from any organism or source, and optionally as shown in NCBI accession number BAA14348.1 or AAA52650.1. VEGFA can be from any organism or source, and optionally as shown in NCBI accession number P15692.2. CCL2 can be from any organism or source, and optionally as shown in NCBI accession number NP_002973.1 . CTX-II can be from any organism or source, and optionally as shown in NCBI accession number P02458.3. CRP can be from any organism or source, and optionally as shown in NCBI accession number AAA52075.1 , KAI4083412.1 , or CAA39671 .1 .
[0087] The control profile may be a reference value and / or may be derived from one or more samples, optionally from historical knee osteoarthritis data from a pool of samples with known annotation of KR or KNR. In an embodiment, the control profile is a value that is continually updated as further samples are collected and PROM scores and local and systemic molecular endotype features are measured and correlated. It will be understood that the control profile represents an average of the levels for the selected PROM scores and local and systemic molecular endotypefeatures described herein. Average values may, for example, be the mean values or median values. In an embodiment, the control profile may be obtained experimentally.
[0088] The term “known responder” or “KR” as used herein means a subject with knee osteoarthritis that exhibited an improvement in clinical phenotype post cellbased anti-inflammatory treatment compared to the subject’s clinical phenotype pre cell-based anti-inflammatory treatment. An improvement can, for example, be increased mobility and / or reduced pain post-treatment compared to pre-treatment. The term “known non-responder” or“KNR” as used herein means a subject with knee osteoarthritis that exhibited no change or a worsening in clinical phenotype post cellbased anti-inflammatory treatment compared to the subject’s clinical phenotype pre cell-based anti-inflammatory treatment. No change or a worsening can, for example, be no change in mobility and / or pain post-treatment compared to pre-treatment, or a decrease in mobility and / or increase in pain, respectively.
[0089] In an embodiment, the control profile of KRs or KNRs to the cell-based anti-inflammatory treatment is first obtained by:I) determining a reference profile of one or more reference subjects with knee osteoarthritis, pre cell-based anti-inflammatory treatment, comprising (i) the assessment of knee osteoarthritis and / or the physical activity assessment, (ii) the local molecular endotype feature from the synovial fluid sample from the reference subject, and (iii) the systemic molecular endotype feature from the sample of serum, plasma, and / or urine from the reference subject, wherein the local molecular endotype feature comprises expression profiles of HGF, VEGFA, and CCL2 and wherein the systemic molecular endotype feature comprises expression profiles of CTX-II and CRP;II) determining the assessment of knee osteoarthritis and / or the physical activity assessment of the reference subject post cell-based anti-inflammatory treatment;III) comparing the assessment of knee osteoarthritis and / or the physical activity assessment pre-treatment to the assessment of knee osteoarthritis and / or the physical activity assessment post-treatment in the reference subject;IV) assigning the reference subject to a KR group when the assessment of knee osteoarthritis and / or the physical activity assessment improved post-treatment compared to pre-treatment, and / or assigning the reference subject to a KNR group when the assessment of knee osteoarthritis and / or the physical activity assessment remained the same or worsened post-treatment compared to pre-treatment;V) obtaining the control profile of KRs from the reference profiles in the KR group and / or obtaining the control profile of KNRs from the reference profiles in the KNR group.
[0090] The term “reference subject” as used herein refers to a subject with knee osteoarthritis who has received a cell-based anti-inflammatory treatment and for whom the pre-treatment and post-treatment phenotypes are known. Reference subjects can be classified as “known responders” (or “KRs”). Reference subjects can also be classified as “known non-responders” (or “KNRs”). A KR can be further classified as a Pain Responder, a Function Responder, or a Pain-Function Responder. The term “Pain Responder” as used herein means a subject that shows an improvement in a pain PROM score post cell-based anti-inflammatory treatment compared to pre cellbased anti-inflammatory treatment, wherein the improvement is a reduction in pain. The term “Function Responder” as used herein means a subject that shows an improvement in a function PROM score post cell-based anti-inflammatory treatment compared to pre cell-based anti-inflammatory treatment, wherein the improvement is, for example, an increase in mobility. The term “Pain-Function Responder” as used herein means a subject that shows an improvement in both a pain PROM score and a function PROM score post cell-based anti-inflammatory treatment compared to pre cell-based anti-inflammatory treatment, wherein the improvement is both a reduction in pain and, for example, an increase in mobility. The classifications of Pain Responder, Function Responder, and Pain-Function Responder are not mutually exclusive; a Pain-Function Responder is also a Pain Responder and a Function Responder.
[0091] Classification of a reference subject as a KR or a KNR can be achieved using any suitable method known in the art, for example using Osteoarthritis Research Society International Standing Committee for Clinical Trials Response Criteria Initiative and the Outcome Measures in Rheumatology (OMERACT-OARSI) criteria todetermine whether the clinical phenotype improved, worsened, or remained the same. In one embodiment, OMERACT-OARSI criteria are used to classify the reference subject as a KR or KNR. In one embodiment, OMERACT-OARSI criteria are used to classify a KR as a Pain Responder, a Function Responder, or a Pain-Function Responder.
[0092] Step II) can be performed at any suitable interval following the cell-based anti-inflammatory treatment, including 1 week, 2 weeks, 3 weeks, 4 weeks, 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 8 months, 10 months, 12 months, 18 months, 24 months, 3 years, 4 years, 5 years, 6 years, 8 years, 10 years, or longer following the cell-based anti-inflammatory treatment. Accordingly, in some embodiments, step II) is performed 3, 6, 12, or 24 months post cell-based antiinflammatory treatment. In an embodiment, step II) is performed 12 or 24 months post cell-based anti-inflammatory treatment.
[0093] In an embodiment, a higher level of similarity to the control profile is indicated by a higher correlation value computed between the test profile and the control profile, optionally wherein the correlation value is a correlation coefficient. In another embodiment, a lower level of similarity to the control profile is indicated by a lower correlation value computed between the sample test profile and control profile, optionally wherein the correlation value is a correlation coefficient. In one embodiment, the correlation coefficient is a linear coefficient, optionally a Pearson correlation coefficient, or a monotonic coefficient, optionally a Spearman’s correlation coefficient.
[0094] In another embodiment, a high level of similarity is indicated by a Pearson correlation coefficient or a Spearman’s between the test profile and the control profile having an absolute value between 0.5 to 1 , optionally between 0.75 to 1 , and a low level of similarity to the control profile is indicated by a Pearson correlation coefficient or a Spearman’s correlation coefficient between the test profile and the control profile having an absolute value between 0 to 0.5, optionally between 0 to 0.25.
[0095] Methods of determining the similarity between profiles are well known in the art. Methods of determining similarity may in some embodiments provide a non- quantitative measure of similarity, for example, using visual clustering. In otherembodiments, similarity may be determined using methods which provide a quantitative measure of similarity.
[0096] In an embodiment, similarity may be measured by computing a “correlation coefficient”, which is a measure of the interdependence of random variables that ranges in value from -1 to +1 , indicating perfect negative correlation at -1 , absence of correlation at zero, and perfect positive correlation at +1. In an embodiment, the correlation coefficient may be a linear correlation coefficient, for example, a Pearson product-moment correlation coefficient.
[0097] A Pearson correlation coefficient (r) is calculated using the following formula:
[0098] In an embodiment, the correlation coefficient may be a monotonic correlation coefficient, for example, a Spearman’s rank correlation coefficient.
[0099] A Spearman’s rank correlation coefficient (p) is calculated using the following formula:where cov(R(X),R(Y)) is the covariance of rank variables and OR(X) and ORCO are their standard deviations.
[0100] In one embodiment, x and y are the PROM scores or local or systemic molecular endotype feature values in a sample profile and a control profile, respectively.
[0101] In an embodiment, a correlation coefficient calculated between a sample immune gene expression profile and a control profile indicates a high level of similarity to the control profile when the correlation coefficient has an absolute value between0.5 to 1 , optionally between 0.75 to 1 , and a low level of similarity to the control profile when the correlation coefficient has an absolute value between 0 to 0.5, optionally between 0 to 0.25.
[0102] It will be appreciated that any “correlation value” which provides a quantitative scaling measure of similarity between profiles may be used to measure similarity.
[0103] In an embodiment, the PROM scores or local or systemic molecular endotype feature is analyzed using combinatorial or multivariate dimension reduction statistical or mathematical methods. Combinatorial or multivariate dimension reduction statistical or mathematical methods may be clustering analyses or desirability analyses to enable comparisons between gene profiles with dimension-reduced empirical values.
[0104] In an embodiment, the clustering analysis is principal component analysis. Principal component analysis is applied as an unbiased tool to visualize similarity between the PROM scores or local or systemic molecular endotype feature of different groups (e.g., a KR specific control profile, a KNR specific control profile, and a sample profile). In another embodiment, the clustering analysis is canonical correlation analysis. Canonical correlation analysis is applied as a supervised technique to test whether multivariate gene profiles of different groups are statistically distinct, and to provide information on their level of similarity.
[0105] In yet another aspect, the present disclosure provides a method of treating knee osteoarthritis comprising administering a cell-based anti-inflammatory treatment to a subject that has been previously identified as having a responder profile, wherein the responder profile has been identified by determining a similarity of a) a test profile comprising (i) a patient-reported outcome measure (PROM) score from an assessment of knee osteoarthritis and / or a physical activity assessment, (ii) a local molecular endotype feature from a synovial fluid sample from the subject, wherein the local molecular endotype feature comprises expression profiles of hepatocyte growth factor (HGF), vascular endothelial growth factor A (VEGFA), and chemokine C-C motif ligand 2 (CCL2), and (iii) a systemic molecularendotype feature from a sample of serum, plasma, and / or urine from the subject, wherein the systemic molecular endotype feature comprises expression profiles of C-telopeptide of type II collagen (CTX-II) and C- reactive protein (CRP); and b) a control profile comprising (i) the PROM score from the assessment of knee osteoarthritis and / or a physical activity assessment of known responders (KRs) to the cell-based anti-inflammatory treatment, (ii) the local molecular endotype feature from the synovial fluid sample of KRs to the cell-based anti-inflammatory treatment, and (iii) the systemic molecular endotype feature from the sample of serum, plasma, and / or urine of KRs to the cell-based anti-inflammatory treatment.
[0106] In another aspect, the present disclosure provides a use of a cell-based anti-inflammatory treatment for treating knee osteoarthritis in a subject that has been previously identified as having a responder profile, wherein the responder profile has been identified by determining a similarity of a) a test profile comprising (i) a patient-reported outcome measure (PROM) score from an assessment of knee osteoarthritis and / or a physical activity assessment, (ii) a local molecular endotype feature from a synovial fluid sample from the subject, wherein the local molecular endotype feature comprises expression profiles of hepatocyte growth factor (HGF), vascular endothelial growth factor A (VEGFA), and chemokine C-C motif ligand 2 (CCL2), and (iii) a systemic molecular endotype feature from a sample of serum, plasma, and / or urine from the subject, wherein the systemic molecular endotype feature comprises expression profiles of C-telopeptide of type II collagen (CTX-II) and C- reactive protein (CRP); and b) a control profile comprising (i) the PROM score from the assessment of knee osteoarthritis and / or a physical activity assessment of known responders (KRs) to the cell-based anti-inflammatory treatment, (ii) the local molecular endotype feature from the synovial fluid sample of KRs to the cell-based anti-inflammatory treatment, and (iii) the systemicmolecular endotype feature from the sample of serum, plasma, and / or urine of KRs to the cell-based anti-inflammatory treatment.
[0107] In another aspect, the present disclosure provides a use of a cell-based anti-inflammatory treatment in the manufacture of a medicament for treating knee osteoarthritis in a subject that has been previously identified as having a responder profile, wherein the responder profile has been identified by determining a similarity of a) a test profile comprising (i) a patient-reported outcome measure (PROM) score from an assessment of knee osteoarthritis and / or a physical activity assessment, (ii) a local molecular endotype feature from a synovial fluid sample from the subject, wherein the local molecular endotype feature comprises expression profiles of hepatocyte growth factor (HGF), vascular endothelial growth factor A (VEGFA), and chemokine C-C motif ligand 2 (CCL2), and (iii) a systemic molecular endotype feature from a sample of serum, plasma, and / or urine from the subject, wherein the systemic molecular endotype feature comprises expression profiles of C-telopeptide of type II collagen (CTX-II) and C- reactive protein (CRP); and b) a control profile comprising (i) the PROM score from the assessment of knee osteoarthritis and / or a physical activity assessment of known responders (KRs) to the cell-based anti-inflammatory treatment, (ii) the local molecular endotype feature from the synovial fluid sample of KRs to the cell-based anti-inflammatory treatment, and (iii) the systemic molecular endotype feature from the sample of serum, plasma, and / or urine of KRs to the cell-based anti-inflammatory treatment.
[0108] In another aspect, the present disclosure provides a use of a cell-based anti-inflammatory treatment for treating knee osteoarthritis in a subject that has been previously identified as having a responder profile by a method herein disclosed. In yet In another aspect, the present disclosure provides a use of a cell-based antiinflammatory treatment in the manufacture of a medicament for treating kneeosteoarthritis in a subject that has been previously identified as having a responder profile by a method herein disclosed. In further aspect, the present disclosure provides a cell-based anti-inflammatory treatment for use in treating knee osteoarthritis in a subject that has been previously identified as having a responder profile by a method herein disclosed.
[0109] In yet another aspect, the present disclosure provides a cell-based antiinflammatory treatment for use in treating knee osteoarthritis in a subject that has been previously identified as having a responder profile, wherein the responder profile has been identified by determining a similarity of a) a test profile comprising (i) a patient-reported outcome measure (PROM) score from an assessment of knee osteoarthritis and / or a physical activity assessment, (ii) a local molecular endotype feature from a synovial fluid sample from the subject, wherein the local molecular endotype feature comprises expression profiles of hepatocyte growth factor (HGF), vascular endothelial growth factor A (VEGFA), and chemokine C-C motif ligand 2 (CCL2), and (iii) a systemic molecular endotype feature from a sample of serum, plasma, and / or urine from the subject, wherein the systemic molecular endotype feature comprises expression profiles of C-telopeptide of type II collagen (CTX-II) and C- reactive protein (CRP); and b) a control profile comprising (i) the PROM score from the assessment of knee osteoarthritis and / or a physical activity assessment of known responders (KRs) to the cell-based anti-inflammatory treatment, (ii) the local molecular endotype feature from the synovial fluid sample of KRs to the cell-based anti-inflammatory treatment, and (iii) the systemic molecular endotype feature from the sample of serum, plasma, and / or urine of KRs to the cell-based anti-inflammatory treatment.
[0110] In an embodiment, the expression profile of CTX-II is from urine and / or the expression profile of CRP is from serum.
[0111] In an embodiment, the systemic molecular endotype feature further comprises an expression profile of interleukin 6 (IL-6) and / or cartilage oligomeric matrix protein (COMP).
[0112] In an embodiment, the expression profile of IL-6 and / or COMP is from plasma.
[0113] IL-6 can be from any organism or source, and optionally as shown in NCBI accession number NP_001305024.1 , NP_001358025.1 , or XP_005249802.1 . COMP can be from any organism or source, and optionally as shown in NCBI accession number P49747.2, KAI4041475.1 , or KAI4041474.1.
[0114] In an embodiment, the local molecular endotype feature further comprises an expression profile of resistin and / or TIMP metallopeptidase inhibitor 1 (TIMP1). In another embodiment, the systemic molecular endotype feature further comprises an expression profile of tumor necrosis factor alpha (TNFa) and / or C1 -2C collagen type I and II cleavage (C1-2C).
[0115] In an embodiment, the expression profile of TNFa is from plasma and / or the expression profile of C1-2C is from serum.
[0116] Resistin can be from any organism or source, and optionally as shown in NCBI accession number AAO38860.1 or AAG59824.1 . TIMP1 can be from any organism or source, and optionally as shown in NCBI accession number KAI2599233.1 , KAI2599231 .1 , or AAH00866.1 . TNFa can be from any organism or source, and optionally as shown in NCBI accession number ADV31546.2 or CAA26669.1. C1-2C is an a-chain fragment of type II collagen that is produced through collagenase cleavage. Type II collagen can be from any organism or source, and optionally as shown in NCBI accession number AAC41772.1 or P02458.3. C1-2C can be produced from type II collagen as described in Dejica et al., 2012
[0057] ,
[0117] In an embodiment, the local molecular endotype feature further comprises an expression profile of soluble CD163 (sCD163). In another embodiment the systemic molecular endotype feature further comprises S100A8 / A9 heterodimer (S100A8 / A9).
[0118] In an embodiment, the expression profile of S100A8 / A9 is from serum.
[0119] sCD163 can be from any organism or source, and optionally as shown in NCBI accession number Q86VB7.2. S100A8 / A9 heterodimer can be from any organism or source, and comprises S100-A8, optionally as shown in NCBI accession number NP_001306125.1 or NP_001306126.1 , and S100-A9, optionally as shown in NCBI accession number NP_002956.1.
[0120] In yet another embodiment, the local molecular endotype feature further comprises an expression profile of adipsin and / or matrix metalloproteinase 13 (MMP- 13). MMP-13 can be from any organism or source, and optionally as shown in NCBI accession number AAU13907.1 or AAH74807.1 .
[0121] The cell-based anti-inflammatory treatment can comprise any cell-based anti-inflammatory treatment known in the art. In an embodiment, the cell-based antiinflammatory treatment comprises mesenchymal stromal or stem cells, bone marrow aspirate, bone marrow aspirate concentrate, autologous fat transfer, concentrated adipose tissue, stromal vascular fraction, platelet-rich plasma, particulate or tissue derived from the placenta and / or amniotic membrane, autologous protein solution, or autologous conditioned serum.
[0122] In another embodiment, the cell-based anti-inflammatory treatment comprises the mesenchymal stromal cells. In one embodiment, the mesenchymal stromal cell is a bone marrow derived mesenchymal stromal cell (MSC(M)). In one embodiment, the mesenchymal stromal cell is an adipose tissue derived mesenchymal stromal cell (MSC(AT)). In another embodiment, the mesenchymal stromal cell is a decidual, dental pulp, or synovial mesenchymal stromal cell. In yet another embodiment, the mesenchymal stromal cells are autologous mesenchymal stromal cells. In a further embodiment, the mesenchymal stromal cell is an immunomodulatorily fit mesenchymal stromal cell [54,55],
[0123] The synovial fluid sample and / or the sample of serum, plasma, and / or urine used to determine the local or systemic molecular endotype feature in the subject may have been collected at different intervals prior to the cell-based anti-inflammatory treatment, for example on the day of the cell-based anti-inflammatory treatment or at 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 2 weeks, 3 weeks, 1 month, or more prior to the cell-based anti-inflammatory treatment. In one embodiment, thesynovial fluid sample and / or the sample of serum, plasma, and / or urine was obtained between one month prior to and immediately prior to the cell-based anti-inflammatory treatment.
[0124] In an embodiment, the sample of serum, plasma, and / or urine comprises serum. In another embodiment, the sample of serum, plasma, and / or urine comprises urine. In another embodiment, the sample of serum plasma, and / or urine comprises plasma. In yet another embodiment, the sample of serum, plasma, and / or urine comprises serum and urine.
[0125] The methods described herein are suitable for use in subjects that have not received a previous treatment for knee osteoarthritis and for subjects that have received prior treatments for knee osteoarthritis. Accordingly, in one embodiment, the subject has not received a previous treatment for knee osteoarthritis. In another embodiment, the subject has previously received at least one treatment for knee osteoarthritis.
[0126] The assessment of knee osteoarthritis can comprise any method known in the art to assess knee osteoarthritis. In some embodiments, the assessment of knee osteoarthritis comprises Knee injury and Osteoarthritis Outcome Score (KOOS), Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), Visual Analogue Scale (VAS), Short Form 36 (SF-36) or Short Form 12 (SF-12), Tegner Lysholm Knee Score, Knee Society Clinical Rating System, Lequesne Index for Knee Osteoarthritis, Oxford Knee Score (OKS) and / or International Knee Documentation Committee (IKDC) Questionnaire.
[0127] In one embodiment, the assessment of knee osteoarthritis comprises KOOS and the PROM score comprises Function in Sports and Recreation (Sports / Rec) and / or Overall KOOS.
[0128] In another embodiment, the assessment of knee osteoarthritis comprises WOMAC and the PROM score comprises Overall WOMAC.
[0129] The physical activity assessment can be any assessment known in the art to assess physical activity. In some embodiments, the physical activity assessment comprises Marx Activity Rating Scale (MARS), SF36 Physical Function Score,International Physical Activity Questionnaire (IPAQ), Timed Up and Go Test (TUG), and / or 6 Minute Walk T est.
[0130] The term “administering” or “administration” as used herein refers to the placement of a cell-based anti-inflammatory treatment as disclosed herein into a subject by a method or route which results in at least partial delivery to a desired site. The cell-based anti-inflammatory treatment disclosed herein can be administered by any appropriate route which results in an effective treatment in the subject, and can be by injection into the knee, for example by intra-articular injection. The cell-based anti-inflammatory treatment can also be administered, for example, by intravenous administration or intraosseous administration.
[0131] The term “treating”, “treatment”, and the like, as used herein, and as is well understood in the art, refers to an approach for obtaining beneficial or desired results, including clinical results. Beneficial or desired clinical results include, but are not limited to alleviation or amelioration of one or more symptoms or conditions, arresting development of disease, diminishment of extent of disease, stabilized (i.e. not worsening) state of disease, preventing spread of disease, delay or slowing of disease progression, amelioration or palliation of the disease state, including regression of the disease, diminishment of the reoccurrence of disease, and remission (whether partial or total), whether detectable or undetectable. “Treating” and “treatment” may also refer to prolonging survival as compared to expected survival if not receiving treatment.
[0132] The above disclosure generally describes the present application. A more complete understanding can be obtained by reference to the following specific examples. These examples are described solely for the purpose of illustration and are not intended to limit the scope of the application. Changes in form and substitution of equivalents are contemplated as circumstances might suggest or render expedient. Although specific terms have been employed herein, such terms are intended in a descriptive sense and not for purposes of limitation.Examples
[0133] The following non-limiting Examples are illustrative of the present disclosure:Example 1 - Osteoarthritis patient responders versus non-responders to mesenchymal stromal cell therapy are determined by differential KOOS phenotype and molecular endotype
[0134] Herein, the inventors report new clinical data out to 24-months followup, categorizing patient responses based on function and pain response thresholds. Furthermore, the inventors identified differential baseline clinical phenotype and molecular endotype features of knee OA patients that were distinct for responder patients as compared to non-responders and correlated to improvements in patient reported outcome measures (PROMs) at 12- and 24-months after injection of autologous MSC(M).
[0135] Methods
[0136] Study Design and Patients
[0137] Patients were recruited to this nonrandomized, open-label, doseescalation phase l / ll clinical trial with informed consent as previously reported
[0010] (ClinicalTrials.gov Identifier: NCT02351011). Ethics approval was granted by the UHN Research and Ethics Board (REB 14-7909) and Health Canada. Eligibility criteria included: i) radiographic and symptomatic knee OA, Kellgren-Lawrence (KL) grade III- IV; ii) Age: 40-65 years; Body Mass Index (BMI) < 30; iii) failed conservative management for a minimum of 6 months; iv) no history of intra-articular hyaluronic acid, cortisone, or platelet-rich plasma within the previous six months; v) clinically stable knee; and, vi) relatively neutral knee alignment (<5 degrees, measured by 4- foot standing antero-posterior radiographs), as well as other inclusion / exclusion criteria detailed previously
[0010] . Patients received a single intra-articular autologous MSC(M) injection at doses of 1 x 106, 10 x 106, and 50 x 106cells (N=4 patients / dose group). Clinical follow-up was performed over 24 months after MSC(M) injection. The Knee injury and Osteoarthritis Outcome Score (KOOS) was applied as a patient- reported outcome measurement tool
[0021] and the scale was inverted such that higher scores indicate worse outcomes. Both delta and percentage change KOOS values were calculated using scores collected at follow-up time points relative to baseline in order to capture absolute changes, as well as changes that account for baseline values, respectively. While delta values correspond to the magnitude of difference relative to baseline, they do not account for differences at baseline; percentagechange values do control for baseline scores but can be inflated when baseline scores are low. Both are considered relevant measures of change according to international criteria for evaluating OA therapeutics
[0022] and are therefore included throughout this study. Delta and percentage change values were calculated such that positive values indicated improvement. The Marx Activity Rating Scale (MARS) was also used as a tool measuring levels of physical activity for individuals with knee disorders
[0023] , Liquid biopsy specimens (plasma, serum, urine, and synovial fluid) were collected at baseline prior to MSC(M) injection as done previously
[0010] , The experimental design is illustrated in Fig. 1
[0138] Biomarker Measurements and Synovial Fluid Monocyte / Macropha e Characterization
[0139] Levels of biomarkers in serum (C1 -2C collagen type I and II cleavage, C1-2C), plasma (hyaluronan, HA; cartilage oligomeric matrix protein, COMP), urine (C-telopeptide of type II collagen, CTX-II; collagen type II cleavage, C2C), and synovial fluid (matrix metalloproteinases, MMP-3, MMP-9, MMP-13; tissue inhibitor of metalloproteinases 1 , TIMP1 ; C-X-C chemokine motif ligands, CX3CL1 , CXCL1 ; chemokine C-C motif ligand 2, CCL2; vascular endothelial growth factor A, VEGFA; interleukin, IL12p40, IL-6, IL-8; hepatocyte growth factor, HGF; soluble CD14, sCD14, sCD163; prostaglandin; adiponectin; adipsin; leptin; and resistin) collected at baseline prior to MSC(M) injection were measured previously
[0010] , Updated analyses and experimental questions were applied to the dataset in the present work. Additional inflammatory biomarkers measured in patient serum collected at baseline were also evaluated by ELISA, including: S100A8 / A9 Heterodimer DuoSet ELISA (R&D Systems, Minneapolis, USA; Cat. DY8226-05), C-reactive protein (CRP) DuoSet ELISA (R&D Systems; Cat. DY1707), and soluble CD163 (sCD163) DuoSet ELISA (R&D Systems; Cat. DY1607). Biomarkers measured by ELISA in patient plasma collected at baseline included: high-sensitivity IL-6 ELISA (ThermoFisher Scientific, Waltham, USA; Cat. BMS213HS), and Quantikine HS TNFa ELISA (R&D Systems; HSTA00E). MO in synovial fluid were characterized based on expression of CD14, CD16, and CD163 measured by flow cytometry, as previously described
[0010] ,
[0140] Statistical Analyses
[0141] GraphPad Prism 6.0 (La Jolla, USA) and JMP Pro 17 (Cary, USA) software were used for statistical analyses and to create plots. Statistical tests are specified in the figure and table captions. Spearman’s correlation was selected as a non-parametric statistical test to investigate associations between KOOS changes (delta or percentage change) and other variables, given that variables within this dataset violated assumptions of normality and homoscedasticity. Spearman’s correlation offers further advantages including that it does not assume linear associations (instead, it assesses monotonic relationships), and that dependent / independent variables do not need to be specified. P values derived from Spearman’s correlation were not corrected for multiple comparisons given that common methods for multiple comparison corrections rely on assumptions of normality. P values less than 0.05 were considered statistically significant.
[0142] Results
[0143] Patient Responder Status to Intra-Articular MSC(M) Injection in Knee Osteoarthritis
[0144] Multivariate factors influencing knee OA patient responder status were investigated following intra-articular injection of autologous MSC(M), including baseline clinical phenotype and baseline molecular endotype. Using KOOS data the inventors reported previously which followed patients to the study endpoint of 12 months
[0010] , criteria from the Osteoarthritis Research Society International Standing Committee for Clinical Trials Response Criteria Initiative and the Outcome Measures in Rheumatology (OMERACT-OARSI)
[0022] were applied to determine responder status, with modifications. The OMERACT-OARSI criteria offers a rigorous classification system developed using data from large, powered placebo-controlled drug trials for hip and knee OA
[0022] , These criteria categorize patients as responders according to the following: i) improvement in pain or in function >50% and absolute change > 20; OR, ii) improvement (>20% and absolute change > 10) in at least two of the following: a) pain, b) function, c) patient global assessment (not measured in our trial). Given the limited sample size and lack of patient global assessment metric in the previous clinical trial, patients were categorized based on changes in KOOS functionin daily living (ADL; corresponding to a function score) and KOOS Pain only, and thresholds were applied selected based on the OMERACT-OARSI criteria for function and pain scores of delta value > 10 and percentage change > 20% to determine responder status
[0022] , KOOS was selected for evaluating responder status, as it is a validated tool for measuring responses to interventions in OA with high test-retest reliability and improved sensitivity in pain and function scoring relative to the WOMAC scoring system [22,24,25], Thus, the criteria applied for determining and classifying responders was more relaxed to accommodate for the smaller sample size and lack of patient global assessment scores, and it consisted of the following groups: i) Function-Pain Responders (patients exceeding thresholds in both ADL and Pain scores), ii) Function Responders (patients exceeding thresholds in ADL scores but not Pain scores), and iii) Pain Responders (patients exceeding thresholds in Pain scores but not ADL scores) (Table 1). Six Function-Pain Responders, seven Function Responder (including the six Function-Pain Responders), and seven Pain Responder (including the six Function-Pain Responders) were identified. The remaining patients were classified as Non-Responders. While the sample size was limited, the binary responder / non-responder criteria were useful for the analyses applied in the present work to determine factors influencing patient clinical responses. Additionally, correlation analyses to all KOOS subscales were included throughout, which does not rely on the responder / non-responder classification criteria to further supplement these analyses.
[0145] Notably, while the clinical trial was under-powered to evaluate dose responses, Function-Pain Responders were observed across all three MSC(M) doses applied in the trial, including the 1x106cell dose (2 / 4 patients), 10x106cell dose (1 / 4 patients), and the 50x106cell dose (3 / 4 patients) (Table 1). One patient within the 10x106cell dose group responded in terms of KOOS Pain (but not ADL) and was classified as a Pain Responder, while another patient within the 50x106cell dose group responded in terms of KOOS ADL (but not pain) and was classified as a Function Responder. These data align with previous findings by the inventors
[0010] and others [26,27] reporting higher doses of > 50x106cells afforded improved patient outcomes, as the inventors recently discussed in a review of MSCs in OA
[0056] , However, varying levels of responses were observed across all dose groups, indicating that other factorsinfluence patient responses to MSC(M) injection, including clinical phenotype and molecular endotype, which were investigated in detail within the present study.
[0146] Positive Responses to Intra-Articular MSC(M) Injection Are Maintained out to 24 Months Follow-Up in Knee Osteoarthritis Patients
[0147] Using new data out to two years follow-up for this clinical trial cohort, the inventors determined that patient responses as evaluated by KOOS were maintained over this two-year period (Fig. 2). Specifically, patients categorized as Function-Pain Responders displayed significantly improved KOOS Symptoms, Pain, ADL, Sports / Rec, QOL, and Overall KOOS at both 12- and 24-months follow-up relative to baseline as indicated by reduced scores (Fig. 2), indicating that positive effects of autologous MSC(M) in knee OA persisted out to 24 months with a single injection. In contrast, patients categorized as Non-Responders showed no significant changes in each of the KOOS subscales and Overall KOOS at 12- and 24-months relative to baseline, indicating that the clinical phenotype of this group neither improved nor worsened compared to baseline.
[0148] Similar results were obtained when patients were categorized according to either Function Responders or Pain-Responders; however, the improvements in Sports / Rec scores were observed only at the 12- and not the 24-month time point relative to baseline for these Function Responders (Fig. 3A) and Pain Responders (Fig. 3B)
[0149] More Severe Clinical Phenotypes at Baseline Correlate to 12- and 24- Month Improvements in Patient-Reported Outcomes
[0150] To probe the relationship between baseline clinical phenotype and patient outcomes, baseline KOOS subscales were analyzed according to responder / non-responder categories and in correlation with changes in specific KOOS subscales over time (positive delta or percent change values indicate improvement) (Fig. 4A - Fig. 4D). While not statistically significant, Function-Pain Responders displayed elevated baseline scores across all five KOOS subscales and Overall KOOS compared to Non-Responders, suggestive of greater disease severity at baseline within the Function-Pain Responder group (Fig. 4A). A similar trend was observed for patients classified as Pain Responders (Fig. 5). Interestingly, patients classified asFunction Responders displayed significantly elevated Overall KOOS and KOOS Sports / Rec at baseline compared to the Non-Responder group (Fig. 4B).
[0151] Next, correlations between the baseline scores for all five KOOS subscales (which can inform baseline clinical phenotype of patients
[0018] ) as well as Overall KOOS with changes (delta and percentage changes) in these scores at 12- and 24-months relative to baseline were analyzed (representing changes to patient reported outcomes at 12- or 24-months; Table 2). Significant positive correlations were identified between baseline Sports / Rec scores with improvements in i) KOOS ADL at 12 months relative to baseline, and improvements in ii) KOOS ADL, iii) Symptoms, and iv) Overall KOOS at 24 months relative to baseline (Fig. 4C). This indicates that more severe Sports / Rec functional scores at baseline correlated to greater improvements in daily function (KOOS ADL), overall disease severity (Overall KOOS), and other symptoms such as swelling and mechanical issues with the knee (KOOS Symptom).
[0152] Given that the KOOS Sports / Rec score measures activity associated with knee function, including squatting, running, jumping, pivoting, and kneeling
[0021] , the relationship between the KOOS Sports / Rec score and physical activity was further probed using the MARS as a readout for the level of physical activity involving high functional demand for the knee in OA
[0028] , These analyses demonstrated that patients with high MARS scores (indicative of more frequent physical activity) significantly negatively correlated to lower (i.e. , less severe) KOOS Sports / Rec at baseline (Fig. 4D). Without being bound by theory, this result is intuitive given that greater issues with knee function may correspond to reduced physical activity. Interestingly, a higher frequency of physical activity at baseline, indicated by higher MARS scores, significantly negatively correlated to changes in i) KOOS Symptoms, and ii) KOOS Pain at 12 months (Fig. 4D, Table 3). Thus, patients with a more severe clinical phenotype at baseline, particularly related to functional challenges evaluated by KOOS Sports / Rec scores, tended to have lower levels of physical activity which may have resulted from reduced knee function. Nonetheless, this cohort of patients seemed to respond more robustly to MSC(M) injection, as evidenced by improvement in ADL function scores, and other KOOS subscales based on the limited twelve-patient dataset.
[0153] Local Molecular Endotype Features at Baseline Correlate to 3-, 12- and 24-Month Improvements in Patient-Reported Outcomes
[0154] In addition to the analysis of baseline clinical phenotype, curated panels of local and systemic inflammatory, angiogenic, metabolic, and cartilage extracellular matrix-associated biomarkers measured at baseline were analyzed and correlated with patient responses to the MSC(M) injections. The levels of biomarkers in synovial fluid were previously reported by the inventors
[0010] ; however, new analytical questions were posed which focused on correlations of biomarker levels at baseline prior to MSC(M) injection with KOOS improvements (Tables 4 to 7). It should be noted that synovial fluid collection was feasible for only nine patients, due to failed athrocentesis for several patients at the time of injection. These nine patients included five Function- Pain Responders and one Function Responderwhich circumvented the utility of binary comparisons between responders and non-responders.
[0155] Correlation analyses revealed several biomarkers measured in the synovial fluid at baseline that significantly correlated with improvements in KOOS Sports / Rec scores at 12 and 24 months relative to baseline. The adipokine, resistin, was significantly positively correlated with greater improvements (delta values) in Sports / Rec scores at 24 months relative to baseline (Fig. 6A). In parallel, lower levels of the MMP inhibitor, TIMP1 , significantly negatively correlated to percentage changes in KOOS Sports / Rec scores at 24 months relative to baseline. Correlation analyses further revealed that levels of the chemokine CCL-2 significantly negatively correlated with changes (delta and percent change values) in KOOS Sports / Rec scores at 24 months relative to baseline (Fig. 6A). Significant negative correlations were also observed between changes in KOOS pain at 12 months relative to baseline with the levels of the pleiotropic growth factor HGF, as well as the potent angiogenic factor VEGFA (Fig. 6B).
[0156] Significant negative correlations were observed for baseline synovial fluid levels of sCD14 and CCL2 with changes in KOOS Symptoms and Sports / Rec scores at 3 months relative to baseline (Fig. 6C, Tables 6, 7) when patients displayed early improvements in PROMs according to the previous study
[0010] , No significantcorrelations were observed for local synovial fluid biomarkers and KOOS subscales at the 6-month time point (Tables 6, 7).
[0157] Baseline Synovial Fluid Levels of CD14+CD16+ and CD14+CD163+ Monocyte / Macrophac / es Trend Lower in Function-Pain Responders
[0158] The presence of MO subpopulations within the synovial fluid at baseline was further probed; however, analysis was possible only for five samples (including from three Function-Pain Responders and two Non-Responders) due to volume limitations of collecting synovial fluid. Nonetheless, a trend was observed such that patients classified as Function-Pain Responders displayed lower levels of baseline CD14+CD16+(intermediate MO subtype) and higher baseline levels of CD14+CD16negMO (classical MO subtype) (Fig. 7A and Fig. 7B), which were correlated inversely and positively to PROMs, respectively, in the inventors’ previous work
[0029] , In parallel, a trend toward lower levels of the CD14+CD163+MO subpopulation was observed in Function-Pain Responders versus Non-Responders (Fig. 7C), similar to the trend observed for the CD14+CD16+intermediate MO subtype.
[0159] Baseline Systemic Biomarker Levels Correlate With 3- and 6-Month but Not 12- and 24-Month Patient-Reported Outcome Measures
[0160] Levels of inflammatory biomarkers (sCD163, CRP, S100A8 / A9, TNFa, and IL-6) were measured in the serum and plasma of all twelve patients at baseline (Table 8). Correlations were assessed between changes in KOOS with baseline levels of these biomarkers, as well as systemic biomarkers of cartilage breakdown measured in the inventors’ previous study
[0010] , including serum C1-2C, plasma COMP and HA, and urine CTX-II and C2C. Results of these analyses demonstrated no significant correlations between the levels of these biomarkers at baseline with any changes in KOOS at the 12- and 24-month time points (Table 9). However, analyses at shorter time points indicated that higher levels of TNFa in plasma at baseline significantly positively correlated to the percentage change in KOOS Pain as well as KOOS QOL improvement at 6 months relative to baseline (Fig. 8A, Table 10). Moreover, serum levels of the alarmin S100A8 / A9 measured at baseline were significantly negatively correlated to changes (delta or percentage values) in KOOS QOL, and Sports / Rec at 3 months relative to baseline (Fig. 8B, Table 10). Systemic levels of biomarkers forcartilage breakdown showed no significant correlations to changes in KOOS at the 6- and 3-month time points. Altogether, without being bound by theory, these results indicate that local biomarkers within synovial fluid may provide greater correlative sensitivity compared to systemic biomarkers to 12- and 24-month patient outcomes to MSC(M) injections. These analyses thus reveal specific biomarkers that have utility in identifying molecular endotypes of patients who are more likely to respond to MSC(M) injection in OA.
[0161] Discussion
[0162] In the present study, the inventors showed that effects of intra-articular autologous MSC(M) injection in knee OA remain stable out to two years post-injection and the influence of baseline patient factors on PROMs was investigated. Within the cohort of twelve patients, a set of baseline factors was identified for patients who displayed improved responses to MSC(M) injection, including: reduced knee functionality associated with sports and recreation, reduced physical activity, and a signature of correlative local and systemic biomarkers.
[0163] In the analysis of baseline clinical phenotype, patients who responded well to MSC(M) injection generally displayed more severe OA symptoms prior to MSC(M) injection. In particular, patients with greater challenges in higher functioning of the knee (KOOS Sports / Rec) and reduced frequency of physical activity (MARS) showed greater improvements in knee function, pain, and other symptoms at 12- and 24-months after MSC(M) injection. Without being bound by theory, the demographics of the cohort may provide clues on the utility of the Sports / Rec measurement as a correlative baseline score for PROM improvements in this study; the inclusion criteria specified an age range of 40-65 years, BMI <30, and relatively neutral (<5 degrees varus / valgus) knee alignment, all of which are associated with levels of physical activity in knee OA patients [30-32], supportive of greater relevance of this KOOS subscale in the present cohort.
[0164] Due to the limited sample size, baseline clinical phenotype was analyzed according to three different responder criteria: Function-Pain Responders (responding in both KOOS ADL and Pain), Function Responders (responding in KOOS ADL), and Pain Responders (responding in KOOS Pain). An overall greater distinction betweenknee OA symptom severity was observed at baseline in patients classified as Function Responders relative to Non-Responders, in particular for the baseline KOOS Sports / Rec score. This suggests that greater improvements in daily functioning of the knee (KOOS ADL) resulted from MSC(M) treatment in patients with greater challenges in high-level functioning of the knee (KOOS Sports / Rec) due to inter-relationships between these two subscales
[0021] , This result is interesting given that MSCs are thought to have large analgesic effects based on meta-analyses [33,34]; however, the present findings may be due to the patient inclusion criteria and limited sample size, as well as temporal changes in PROMs, given that responder categorization was performed based on outcomes at 12 months. Notably, correlations were included between baseline data with improvements in PROMs throughout the study to supplement binary responder / non-responder comparisons. In calculating PROM improvements, both percentage change and delta values were included, which are mathematically and conceptually distinct and are both considered relevant measures of change by OARSI-OMERACT
[0022] , Both measures of change provided useful information within the present study, and while significant correlations were presented within the figures, all correlations (significant and non-significant) were included within the tables.
[0165] To further probe patient factors at baseline, local and systemic levels of inflammatory, angiogenic, metabolic, and extracellular matrix-associated biomarkers were measured to gain insight into the baseline molecular endotype of knee OA patients within the present cohort. Patients who responded well in terms of KOOS Sports / Rec, Pain, or other Symptoms displayed a mixed signature of higher levels of the adipokine (resistin), and lower levels of inflammation-, angiogenesis-, and extracellular matrix-associated biomarkers, including TIMP1 , CCL2, HGF, VEGFA, and sCD14 within the synovial fluid at baseline. While increased levels of resistin in synovial fluid may be linked to higher levels of inflammation in knee OA
[0035] , lower levels of HGF, TIMP1 , VEGFA, CCL2, and sCD14 may indicate lower levels of active inflammation and angiogenesis [36-39], Biomarker levels also vary temporally with OA disease stage
[0040] and likely with inflammatory flare-ups
[0041] , and thus, the time point of collection represents a limited snapshot of the disease status. Thus, the local biomarker profile is supportive of both high (resistin) and low (CCL2, HGF, VEGFA,and sCD14) baseline levels of local inflammation correlating with improvements in KOOS Sports / Rec, Pain or Symptoms. Notably, these data align with a previous report demonstrating a mixed signature of increased and decreased levels of various inflammatory biomarkers measured at baseline in responders versus non-responders to intravenous infusion of allogeneic Wharton’s jelly-derived MSCs in rheumatorid arthritis patients
[0053] ,
[0166] In addition to the measurement of biomarkers, the inventors investigated synovial fluid MO subsets and found a general trend of lower levels of CD14+CD16+(intermediate MO) and CD14+CD163+MO, along with higher levels of CD14+CD16neg(classical MO) in synovial fluid collected at baseline from Function-Pain Responders versus Non-Responders, albeit with a limited sample size of five synovial fluid specimens. Notably, the functionality of these MO subtypes within the context of OA is likely mixed, as they have been shown to co-express various markers that are considered putative pro-inflammatory as well as inflammation-resolving markers, as the present inventors and others have demonstrated [29,42], Interestingly, the lower levels of local intermediate and mixed phenotype MOs and the lower levels of local inflammatory biomarkers (CCL2, HGF, VEGFA, and sCD14) seem to associate together.
[0167] Part of the challenge in identifying patterns of local molecular endotypes based on biomarkers or immune cell subsets relates to volume limitations in collecting synovial fluid from patients, which was possible only for nine patients, and volumes precluded full biomarker and immune cell profiling for all nine samples. Given that the volume of synovial fluid in the joint has been shown to correlate to increased inflammation and greater joint pain [43,44], these data indicate that the patients from whom these samples were collected may have had active synovitis at the time of collection and MSC(M) injection, and thus already represent a subset of OA patients with active disease processes. However, within the limited sample size for which inflammation may already be elevated, lower baseline levels of inflammatory and angiogenic biomarkers within synovial fluid correlated to improved responses, indicating that some balance between synovial fluid volumes and levels of these biomarkers may be informative. While the sample size is limited, the present study provides useful insights into molecular endotype features, including local biomarkersand immune cell profiling that can help to stratify knee OA patients for MSC(M) therapy.
[0168] There are ongoing efforts to identify specific molecular endotypes based on local synovial fluid biomarker profiles, and to correlate these with patient clinical phenotypes using large cohorts of OA patients and unbiased proteomic approaches, as was recently presented
[0045] , While still in progress, preliminary data suggests an absence of correlation
[0045] , However, the present study was interventional, representing a strength that allowed the inventors to examine differences in baseline synovial fluid and systemic biomarkers in correlations with responses to the MSC(M) injection. Furthermore, previous work has provided insights into relationships between molecular endotype and clinical phenotype features, [19,36] and their complexity given that both fluctuate temporally and display combinations of unique and overlapping signatures, representing an active area of research that will further aid in stratifying OA patients for therapy [18,20],
[0169] In parallel to the measurement of local biomarkers, the inventors also measured levels of systemic biomarkers, including inflammatory mediators and indicators of cartilage breakdown within the blood and urine at baseline. These markers were selected based on literature that has shown associations between these biomarkers with increased cartilage damage and / or more severe PROMs [36,46,47], Statistically significant correlations were observed only at the 3- and 6-month time points for the inflammatory mediators TNFa (in plasma) and S100A8 / A9 (in serum) which positively and negatively correlated to PROM improvements, respectively. Higher circulating levels of both TNFa and S100A8 / A9 may correlate to greater disease severity and systemic inflammation [46,48], However, other factors, including comorbidities and underlying health conditions can influence levels of inflammatory biomarkers. Within the present cohort, patients presented with a variety of other health conditions, including multiple joint OA, metabolic disorders, asthma, and mental health conditions, all of which may be associated with systemic inflammation [49-52], The present data indicate that local biomarkers can provide improved sensitivity compared to systemic biomarkers in terms of correlations to 12- and 24-month improvements after MSC(M) injection [19,36],
[0170] Taken together, the findings from the present study reveal specific baseline PROMs and biomarker profiles that provide insight into the clinical phenotype and molecular endotype of knee OA patients who responded robustly to autologous intra-articular MSC(M) injection. The inventors’ approach provides a means to stratify patients for MSC therapies to treat knee OA patients with intra-articular MSC injections.Example 2 - Osteoarthritis patient responders versus non-responders to mesenchymal stromal cell therapy are determined by differential WOMAC phenotype and molecular endotype
[0171] The inventors performed a similar set of analyses to those described in Example 1 but using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) rather than KOOS to evaluate patient reported outcome measures (PROMs).
[0172] Methods
[0173] Study Design and Patients
[0174] The study design and patients were as described in Example 1 , wherein KOOS was substituted with WOMAC. WOMAC consists of three subscales: Pain, Stiffness, and Function. WOMAC and KOOS are related. KOOS is an extension of WOMAC; the WOMAC Function scale is identical to the KOOS ADL subscale, while the KOOS Pain and Symptoms subscales incorporate WOMAC Pain and Stiffness, respectively, with additional questions included in the KOOS scale.
[0175] Biomarker Measurements, Synovial Fluid Monocyte / MacrophaqeCharacterization, and Statistical Analyses
[0176] Biomarker measurements, synovial fluid monocyte / macrophage characterization, and statistical analyses were performed as in Example 1. P values less than 0.05 were considered statistically significant.
[0177] Results
[0178] Clinical Phenotype Features
[0179] Baseline WOMAC scores were analyzed according to three sets of patient responder criteria as specified in Example 1 , including Function-PainResponders, Function Responders, and Pain Responders. No significant differences in Overall WOMAC scores or WOMAC subscales were observed when comparing Function-Pain Responders (Fig. 9A) and Pain Responders (Fig. 9C) to NonResponders, similar to the analysis of KOOS scores.
[0180] Similar to the findings observed for KOOS, the Overall WOMAC scores were significantly higher in patients classified as Function Responders relative to Nonresponders, indicating that patients who demonstrated functional improvements after MSC(M) injection showed greater disease severity and clinical phenotype at baseline (Fig. 9B). While scores trended higher in Function Responders for all WOMAC subscales, no significant differences were observed between Function Responders and Non-Responders.
[0181] Correlations between baseline WOMAC scores with changes in WOMAC scores (delta and percentage change values) at 12 and 24 months relative to baseline were examined, as was performed in Example 1 using KOOS data. The results generally support that patients with more severe clinical presentation at baseline demonstrated greater improvements in WOMAC scores at follow-up (Table 11).
[0182] The following baseline WOMAC scores significantly positively correlated (p<0.05) with improvements in WOMAC at 24 months relative to baseline. These data show that higher baseline scores (indicative of more severe clinical presentation) correlated to greater improvements measured by WOMAC.
[0183] Baseline WOMAC Stiffness significantly positively correlated to improvements (delta values) in WOMAC Stiffness at 24 months relative to baseline. Baseline WOMAC Pain significantly positively correlated to improvements in WOMAC Stiffness (delta values) and WOMAC Pain (delta values) at 24 months relative to baseline. Baseline Overall WOMAC significantly positively correlated to improvements in WOMAC Pain (delta values) and Overall WOMAC (delta values) at 24 months relative to baseline.
[0184] The following baseline WOMAC scores significantly positively correlated (p<0.05) with improvements in WOMAC at 12 months relative to baseline. These data show that higher baseline scores (indicative of more severe clinical presentation)correlated to greater improvements measured by WOMAC (Table 11). Baseline WOMAC Pain significantly positively correlated to improvements in WOMAC Pain (delta values) at 12 months relative to baseline. Baseline Overall WOMAC significantly positively correlated to improvements in WOMAC Pain (delta values) at 12 months relative to baseline.
[0185] An exception to the above was observed for the baseline WOMAC Stiffness score which was significantly negatively correlated to improvements in WOMAC Stiffness (percent change values) at 12 months relative to baseline.
[0186] Molecular Endotype Features - Local Synovial Fluid Biomarkers
[0187] Correlations between baseline local biomarker levels with changes in WOMAC scores (delta and percentage change values) at 6, 12 and 24 months relative to baseline were examined, as was performed previously using KOOS data. No significant correlations were observed at 24 months (Table 12).
[0188] The following local biomarkers measured at baseline trended toward positive correlations (p<0.1) with improvements in WOMAC at 12 months relative to baseline. These data show that higher levels of specific local biomarkers in synovial fluid at baseline correlated to greater improvements in WOMAC at follow-up (Table 12)
[0189] Baseline levels of adipsin (adipokine) positively correlated to improvements in WOMAC Stiffness (percentage change values) at 12 months relative to baseline. Baseline levels of resistin (adipokine) positively correlated to improvements in WOMAC Stiffness (delta values) at 12 months relative to baseline. Baseline levels of MMP13 (catabolic marker) positively correlated to improvements in WOMAC Stiffness (delta values) at 12 months relative to baseline.
[0190] The following local biomarkers measured at baseline significantly negatively correlated (p<0.05) with improvements in WOMAC at 12 months relative to baseline. These data show that lower levels of specific local biomarkers in synovial fluid at baseline correlated to greater improvements in WOMAC at follow-up. Baseline levels of HGF (pleiotropic growth factor) significantly negatively correlated to improvements in WOMAC Pain (percentage change and delta values) at 12 monthsrelative to baseline. Baseline levels of VEGFA (angiogenic factor) significantly negatively correlated to improvements in WOMAC Pain (percentage change values) at 12 months relative to baseline.
[0191] The following local biomarkers measured at baseline trended toward negative correlations (p<0.1) with improvements in WOMAC at 12 months relative to baseline. These data show that lower levels of specific local biomarkers in synovial fluid at baseline correlated to greater improvements in WOMAC at follow-up. Baseline levels of VEGFA (angiogenic factor) negatively correlated to improvements in WOMAC Pain (delta values) at 12 months relative to baseline.
[0192] The following local biomarkers measured at baseline significantly positively correlated (p<0.1 ) with improvements in WOMAC at 6 months relative to baseline. These data show that higher levels of specific local biomarkers in synovial fluid at baseline correlated to greater improvements in WOMAC at follow-up (Table 13). Baseline levels of MMP13 (catabolic biomarker) positively correlated to improvements in WOMAC Stiffness (delta values) at 6 months relative to baseline.
[0193] Molecular Endotype Features - Systemic Biomarkers
[0194] The following systemic biomarkers measured at baseline significantly positively correlated (p<0.05) with improvements in WOMAC at 24 months relative to baseline. These data show that higher levels of specific systemic biomarkers at baseline correlated to greater improvements in WOMAC at follow-up (Table 14). Baseline levels of CTXII (cartilage breakdown biomarker) significantly positively correlated to improvements in WOMAC Stiffness (delta values) at 24 months relative to baseline.
[0195] The following systemic biomarkers measured at baseline trended toward positive correlations (p<0.1) with improvements in WOMAC at 24 months relative to baseline. These data show that higher levels of specific systemic biomarkers at baseline correlated to greater improvements in WOMAC at follow-up. Baseline levels of IL6 (inflammatory biomarker) positively correlated to improvements in Overall WOMAC (delta values) at 24 months relative to baseline.
[0196] The following systemic biomarkers measured at baseline significantly positively correlated (p<0.05) with improvements in WOMAC at 12 months relative to baseline. These data show that higher levels of specific systemic biomarkers at baseline correlated to greater improvements in WOMAC at follow-up (Table 14). Baseline levels of CTXII (cartilage breakdown biomarker) significantly positively correlated to improvements in WOMAC Pain (delta values) at 12 months relative to baseline. Baseline levels of COMP (cartilage breakdown biomarker) significantly positively correlated to improvements in WOMAC Stiffness (percentage change values) at 12 months relative to baseline.
[0197] The following systemic biomarkers measured at baseline trended toward positive correlations (p<0.1 ) with improvements in WOMAC at 6 months relative to baseline. These data show that higher levels of specific systemic biomarkers at baseline correlated to greater improvements in WOMAC at follow-up (Table 15). Baseline levels of CTXII (cartilage breakdown biomarker) positively correlated to improvements in WOMAC Pain (delta values) at 6 months relative to baseline.
[0198] The following systemic biomarkers measured at baseline trended toward positive correlations (p<0.1 ) with improvements in WOMAC at 3 months relative to baseline. These data show that higher levels of specific systemic biomarkers at baseline correlated to greater improvements in WOMAC at follow-up (Table 15). Baseline levels of CTXII (cartilage breakdown biomarker) positively correlated to improvements in WOMAC Pain (delta values) at 3 months relative to baseline. Baseline levels of IL6 (inflammatory biomarker) positively correlated to improvements in WOMAC Function (delta values) and Overall WOMAC (delta values) at 3 months relative to baseline. Baseline levels of TNF-alpha (inflammatory biomarker) positively correlated to improvements in WOMAC Function (percentage change values) and Overall WOMAC (percentage change values) at 3 months relative to baseline.
[0199] Summary & Interpretation
[0200] The analysis of baseline WOMAC data indicates that knee OA patients with more severe clinical phenotypes at baseline demonstrate greater improvements after MSC(M) treatment, corroborating the analysis in Example 1 on baseline KOOS data. These data further reveal specific WOMAC subscales measured at baseline thatcorrelated to patient improvements at 12 and 24 months, namely the WOMAC Stiffness and WOMAC Pain subscales, as well as Overall WOMAC subscale. Notably, we previously found significant correlations for the baseline KOOS Sports / Rec subscale with improvements in KOOS at follow-up. The KOOS Sports / Rec score is not captured by WOMAC and thus these scoring systems represent distinct measurements that can be useful for stratifying knee OA patients for MSC (or other cell-based immunomodulatory) treatments.
[0201] Correlations of baseline biomarkers with WOMAC showed some common biomarkers identified based on correlations with KOOS, and additional biomarkers that can have utility in stratifying patients who are more likely to respond to an MSC or other cell-based immunomodulatory therapy for knee OA. A summary of these biomarkers as identified by KOOS and / or WOMAC correlations is provided in Table 16
[0202] While the present disclosure has been described with reference to examples, it is to be understood that the scope of the claims should not be limited by the embodiments set forth in the examples, but should be given the broadest interpretation consistent with the description as a whole.
[0203] All publications, patents and patent applications are herein incorporated by reference in their entirety to the same extent as if each individual publication, patent or patent application was specifically and individually indicated to be incorporated by reference in its entirety. Where a term in the present description is found to be defined differently in a document incorporated herein by reference, the definition provided herein is to serve as the definition for the term.TablesTable 1 : Patients classified as Pain-Function Responders, Function Responders, Pain Responders, or Non-Responders based on changes in KOOS pain and ADL scores at 12 months relative to baseline.Table 2: Correlations between baseline KOOS and changes in KOOS (percent change or delta values) at 12 and 24 months. N=12 patients. Significant correlations (*p<0.05) are bolded.Table 3: Correlations between baseline MARS physical activity scores and changes in KOOS (percent change or delta values) at 12 and 24 months. N=12 patients. Significant correlations (*p<0.05) are bolded.Table 4: Correlations between changes in KOOS (percent change or delta values) at 12 and 24 months with baseline levels of local synovial fluid metabolic, angiogenic, and extracellular matrix-associated biomarkers. N=8-9 patients. Significant correlations (*p<0.05) are bolded.Table 5: Correlations between changes in KOOS (percent change or delta values) at 12 and 24 months with baseline levels of local synovial fluid inflammatory biomarkers. N=8 patients. Significant correlations (*p<0.05) are bolded.Table 6: Correlations between changes in KOOS (percent change or delta values) at 3 and 6 months with baseline levels of local synovial fluid metabolic, angiogenic, and extracellular matrix-associated biomarkers. N=8-9 patients. No significant correlations were observed.Table 7: Correlations between changes in KOOS (percent change or delta values) at 3 and 6 months with baseline levels of local synovial fluid inflammatory biomarkers. N=8 patients. Significant correlations (*p<0.05) are bolded.Table 8: Summary of levels of inflammatory systemic biomarkers measured at baseline in serum or plasma. Levels of sCD163, CRP, and S100A8 / A9 were measured in serum, while TNFa and IL-6 were measured in plasma. N=12 patients.Table 9: Correlations between baseline levels of systemic biomarkers and changes in KOOS (percent change or delta values) at 12 and 24 months. N=12 patients. No significant correlations were observed.Table 10: Correlations between baseline levels of systemic biomarkers and changes in KOOS (percent change or delta values) at 3 and 6 months. N=12 patients. Significant correlations (*p<0.05) are bolded.Table 11 : Correlations between baseline WOMAC and changes in WOMAC (percent change or delta values) at 12 and 24 months relative to baseline. N=12 patients. Spearman’s correlation. WOMAC: Western Ontario and McMaster Universities Osteoarthritis Index.Table 12: Correlations between changes in WOMAC (percent change or delta values) at 12 and 24 months with baseline levels of local synovial fluid biomarkers. N=8-9 patients.Table 13: Correlations between changes in WOMAC (percent change or delta values) at 6 months with baseline levels of local synovial fluid biomarkers. N=8- 9 patients.Table 14: Correlations between baseline levels of systemic biomarkers and changes in WOMAC (percent change or delta values) at 12 and 24 months. N=12 patients.Table 15: Correlations between baseline levels of systemic biomarkers and changes in WOMAC (percent change or delta values) at 3 and 6 months. N=12 patients.Table 16: Summary of biomarkers identified for stratifying subjects as likely responders or non-responders to a cell-based anti-inflammatory treatment for knee osteoarthritis.CITATIONS FOR REFERENCES REFERRED TO IN THE SPECIFICATION[1] Cui A, Li H, Wang D, Zhong J, Chen Y, Lu H. Global, regional prevalence, incidence and risk factors of knee osteoarthritis in population-based studies. EClinicalMedicine 2020;29-30. https: / / doi.Org / 10.1016 / j.eclinm.2020.100587.[2] Loeser RF, Goldring SR, Scanzello CR, Goldring MB. Osteoarthritis: a disease of the joint as an organ. Arthritis Rheum 2012;64:1697-707. https: / / doi.Org / 10.1002 / art.34453.[3] Goldring MB, Goldring SR. Osteoarthritis. J Cell Physiol 2007;213:626-34. https: / / doi.org / 10.1002 / jcp.21258.[4] Kapoor M, Martel-Pelletier J, Lajeunesse D, Pelletier J-P, Fahmi H. Role of proinflammatory cytokines in the pathophysiology of osteoarthritis. Nat Rev Rheumatol 2011 ;7:33-42. https: / / d0i.0rg / l 0.1038 / nrrheum.2010.196.[5] Mathiessen A, Conaghan PG. Synovitis in osteoarthritis: Current understanding with therapeutic implications. Arthritis Res Ther 2017;19. https: / / doi.org / 10.1186 / s13075- 017-1229-9.[6] Gomez-Aristizabal A, Gandhi R, Mahomed NN, Marshall KW, Viswanathan S. Synovial fluid monocyte / macrophage subsets and their correlation to patient-reported outcomes in osteoarthritic patients: A cohort study. Arthritis Res Ther 2019;21. https: / / doi.Org / 10.1186 / S13075-018-1798-2.[7] Go WM, Hunter DJ. Repurposed and investigational disease-modifying drugs in osteoarthritis (DMOADs). Ther Adv Musculoskelet Dis 2022; 14. https: / / doi.Org / 10.1177 / 1759720X221090297.[8] Zhang X, He J, Wang W. Progress in the use of mesenchymal stromal cells for osteoarthritis treatment. Cytotherapy 2021 ;23:459-70. https: / / doi.Org / 10.1016 / j.jcyt.2021.01.008.[9] Molnar V, Pavelic E, Vrdoljak K, Cemerin M, Klaric E, Matisic V, et al. Mesenchymal Stem Cell Mechanisms of Action and Clinical Effects in Osteoarthritis: A Narrative Review. Genes (Basel) 2022; 13. https: / / doi.org / 10.3390 / genes13060949.
[0010] Chahal J, Gomez-Aristizabal A, Shestopaloff K, Bhatt S, Chaboureau A, Fazio A, et al. Bone Marrow Mesenchymal Stromal Cells in Patients with Osteoarthritis Results in Overall Improvement in Pain and Symptoms and Reduces Synovial Inflammation. Stem Cells Transl Med 2019;8:746-757. https: / / doi.org / 10.1002 / sctm.18-0183.
[0011] Bastos R, Mathias M, Andrade R, Amaral RJFC, Schott V, Balduino A, et al. Intra-articular injection of culture-expanded mesenchymal stem cells with or without addition of platelet-rich plasma is effective in decreasing pain and symptoms in knee osteoarthritis: a controlled, double-blind clinical trial. Knee Surgery, Sports Traumatology, Arthroscopy 2020;28:1989-99. https: / / doi.org / 10.1007 / s00167-019- 05732-8.
[0012] EMADEDIN M, LABIBZADEH N, LIASTANI MG, KARIMI A, JAROUGHI NEDA, BOLURIEH TINA, et al. Intra-articular implantation of autologous bone marrow-derived mesenchymal stromal cells to treat knee osteoarthritis: a randomized, triple-blind, placebo-controlled phase 1 / 2 clinical trial. Cytotherapy 2018;20:1238-46. https: / / doi.Org / 10.1016 / j Jcyt .2018.08.005.
[0013] Lamo-Espinosa JM, Mora G, Blanco JF, Granero-Molto F, Nunez-Cordoba JM, Lopez- Elio S, et al. Intra-articular injection of two different doses of autologous bone marrow mesenchymal stem cells versus hyaluronic acid in the treatment of knee osteoarthritis: Long-term follow up of a multicenter randomized controlled clinical trial (phase l / ll). J Transl Med 2018;16. https: / / doi.org / 10.1186 / s12967-018-1591-7.
[0014] Lamo-Espinosa JM, Mora G, Blanco JF, Granero-Molto F, Nunez-Cordoba JM, Sanchez-Echenique C, et al. Intra-articular injection of two different doses of autologous bone marrow mesenchymal stem cells versus hyaluronic acid in the treatment of knee osteoarthritis: Multicenter randomized controlled clinical trial (phase l / ll). J Transl Med 2016; 14. https: / / doi.Org / 10.1186 / S12967-016-0998-2.
[0015] Vega A, Martin-Ferrero MA, Del Canto F, Alberca M, Garcia V, Munar A, et al. Treatment of Knee Osteoarthritis With Allogeneic Bone Marrow Mesenchymal Stem Cells: A Randomized Controlled Trial. Transplantation 2015;99:1681-90. https: / / doi.org / 10.1097 / TP.0000000000000678.
[0016] Gupta PK, Chullikana A, Rengasamy M, Shetty N, Pandey V, Agarwal V, et al. Efficacy and safety of adult human bone marrow-derived, cultured, pooled, allogeneic mesenchymal stromal cells (Stempeucel®): Preclinical and clinical trial in osteoarthritis of the knee joint. Arthritis Res Ther 2016; 18. https: / / d0i.0rg / l 0.1186 / s13075-016-1195- 7.
[0017] lijima H, Isho T, Kuroki H, Takahashi M, Aoyama T. Effectiveness of mesenchymal stem cells for treating patients with knee osteoarthritis: a meta-analysis toward the establishment of effective regenerative rehabilitation. NPJ Regen Med 2018;3:15. https: / / doi.Org / 10.1038 / S41536-018-0041-8.
[0018] Mobasheri A, Saarakkala S, Finnila M, Karsdal MA, Bay-Jensen AC, van Spil WE. Recent advances in understanding the phenotypes of osteoarthritis. F1000Res 2019;8.https: / / doi.Org / 10.12688 / f 10OOresearch.20575.1 .
[0019] Dell’lsola A, Allan R, Smith SL, Marreiros SSP, Steultjens M. Identification of clinical phenotypes in knee osteoarthritis: a systematic review of the literature. BMC Musculoskelet Disord 2016;17:1-12. https: / / doi.org / 10.1186 / s12891-016-1286-2.
[0020] Mobasheri A, Bay-Jensen AC, Gualillo O, Larkin J, Levesque MC, Henrotin Y. Soluble biochemical markers of osteoarthritis: Are we close to using them in clinical practice? Best Pract Res Clin Rheumatol 2017;31 :705-20. https: / / doi.Org / 10.1016 / j.berh.2O18.07.002.
[0021] Roos EM, Lohmander LS. The Knee injury and Osteoarthritis Outcome Score (KOOS): From joint injury to osteoarthritis. Health Qual Life Outcomes 2003;1. https: / / doi.Org / 10.1186 / 1477-7525- 1 -64.
[0022] Pham T, van der Heijde D, Altman RD, Anderson JJ, Bellamy N, Hochberg M, et al. OMERACT-OARSI initiative: Osteoarthritis research society international set of responder criteria for osteoarthritis clinical trials revisited. Osteoarthritis Cartilage 2004;12:389-99. https: / / doi.Org / 10.1016 / j.joca.2004.02.001.
[0023] Marx RG, Stump TJ, Jones EC, Wickiewicz TL, Warren RF. Development and evaluation of an activity rating scale for disorders of the knee. Am J Sports Med 2001 ;29:213-8. https: / / doi.Org / 10.1177 / 03635465010290021601 .
[0024] Roos EM, Roos HP, Lohmander LS. WOMAC Osteoarthritis Index - Additional dimensions for use in subjects with post-traumatic osteoarthritis of the knee. Osteoarthritis Cartilage, vol. 7, W.B. Saunders Ltd; 1999, p. 216-21. https: / / doi.Org / 10.1053 / joca.1998.0153.
[0025] Alviar MJ, Olver J, Brand C, Hale T, Khan F. Do patient-reported outcome measures used in assessing outcomes in rehabilitati on after hip and knee art hroplasty capture issues relevant to patients ? Results of a systematicre view and ICF linking process. J Rehabil Med 2011 ;43:374-81. https: / / doi.org / 10.2340 / 16501977-0801.
[0026] Lu L, Dai C, Du H, Li S, Ye P, Zhang L, et al. Intra-articular injections of allogeneic human adipose-derived mesenchymal progenitor cells in patients with symptomatic bilateral knee osteoarthritis: A Phase i pilot study. Regenerative Med 2020; 15: 1625- 36. https: / / doi.Org / 10.2217 / rme-2019-0106.
[0027] Song Y, Du H, Dai C, Zhang L, Li S, Hunter DJ, et al. Human adipose-derived mesenchymal stem cells for osteoarthritis: a pilot study with long-term follow-up and repeated injections. Regen Med 2018. https: / / doi.org / 10.2217 / rme-2017-0152.
[0028] Marx RG, Stump TJ, Jones EC, Wickiewicz TL, Warren RF. Development and evaluation of an activity rating scale for disorders of the knee. American Journal ofSports Medicine 2001 ;29:213-8. https: / / doi.Org / 10.1177 / 03635465010290021601 .
[0029] Gomez-Aristizabal A, Gandhi R, Mahomed NN, Marshall KW, Viswanathan S. Synovial fluid monocyte / macrophage subsets and their correlation to patient-reported outcomes in osteoarthritic patients: A cohort study. Arthritis Res Ther 2019;21 :1-10. https: / / doi.Org / 10.1186 / S13075-018-1798-2.
[0030] Pellegrini CA, Song J, Chang RW, Semanik PA, Lee J, Ehrlich-Jones L, et al. Change in physical activity and sedentary time associated with 2-year weight loss in obese adults with osteoarthritis. J Phys Act Health 2016;13:461-6. https: / / doi.org / 10.1123 / jpah.2015-0404.
[0031] Batsis JA, Germain CM, Vasquez E, Zbehlik AJ, Bartels SJ. Physical activity predicts higher physical function in older adults: The osteoarthritis initiative. J Phys Act Health 2016; 13:6-16. https: / / doi.Org / 10.1123 / jpah.2014-0531 .
[0032] Wada M, Miyazaki T, Yamamoto Y, Sakamoto T, Adachi T. Correlation of knee laxity with alignment and repetitive physical activity in patients with knee osteoarthritis: A cross-sectional study. Knee 2023;40:111-21. https: / / d0i.0rg / l 0.1016 / j. knee.2022.10.003.
[0033] Cui G-H, Wang YY, Li C-J, Shi C-H, Wang W-S. Efficacy of mesenchymal stem cells in treating patients with osteoarthritis of the knee: A meta-analysis. Exp Ther Med 2016;12:3390-400. https: / / doi.org / 10.3892 / etm.2016.3791.
[0034] lijima H, Isho T, Kuroki H, Takahashi M, Aoyama T. Effectiveness of mesenchymal stem cells for treating patients with knee osteoarthritis: a meta-analysis toward the establishment of effective regenerative rehabilitation. NPJ Regen Med 2018;3:15. https: / / doi.Org / 10.1038 / S41536-018-0041-8.
[0035] Chen WC, Lu YC, Kuo SJ, Lin CY, Tsai CH, Liu SC, et al. Resistin enhances IL-1 p and TNF-a expression in human osteoarthritis synovial fibroblasts by inhibiting miR-149 expression via the MEK and ERK pathways. FASEB Journal 2020;34:13671-84. https: / / doi.Org / 10.1096 / fj.202001071 R.
[0036] Daghestani HN, Pieper CF, Kraus VB. Soluble macrophage biomarkers indicate inflammatory phenotypes in patients with knee osteoarthritis. Arthritis Rheumatol 2015;67:956-65. https: / / doi.org / 10.1002 / art.39006.
[0037] Haraden CA, Huebner JL, Hsueh MF, Li YJ, Kraus VB. Synovial fluid biomarkers associated with osteoarthritis severity reflect macrophage and neutrophil related inflammation. Arthritis Res Ther 2019;21. https: / / doi.org / 10.1186 / s13075-019-1923-x.
[0038] Mabey T, Honsawek S, Saetan N, Poovorawan Y, Tanavalee A, Yuktanandana P. Angiogenic cytokine expression profiles in plasma and synovial fluid of primary kneeosteoarthritis. Int Orthop 2014;38:1885-92. https: / / doi.org / 10.1007 / s00264-014-2406- y-
[0039] Raghu H, Lepus CM, Wang Q, Wong HH, Lingampalli N, Oliviero F, et al. CCL2 / CCR2, but not CCL5 / CCR5, mediates monocyte recruitment, inflammation and cartilage destruction in osteoarthritis. Ann Rheum Dis 2017;76:914-22. https: / / doi.Org / 10.1136 / annrheumdis-2016-210426.
[0040] Heard BJ, Fritzler MJ, Wiley JP, McAllister J, Martin L, El-Gabalawy H, et al. Intraarticular and systemic inflammatory profiles may identify patients with osteoarthritis. J Rheumatol 2013;40:1379-87. https: / / doi.org / 10.3899 / jrheum.121204.
[0041] Thomas MJ, Neogi T. Flare-ups of osteoarthritis: what do they mean in the short-term and the long-term? Osteoarthritis Cartilage 2020;28:870-3. https: / / doi.Org / 10.1016 / j.joca.2020.01.005.
[0042] Ohashi Y, Uchida K, Fukushima K, Satoh M, Koyama T, Tsuchiya M, et al. Correlation between CD163 expression and resting pain in patients with hip osteoarthritis: Possible contribution of CD163+ monocytes / macrophages to pain pathogenesis. Journal of Orthopaedic Research 2022;40:1365-74. https: / / doi.org / 10.1002 / jor.25157.
[0043] Kraus VB, Stabler T V., Kong SY, Varju G, McDaniel G. Measurement of synovial fluid volume using urea. Osteoarthritis Cartilage 2007;15:1217-20. https: / / doi.Org / 10.1016 / j.joca.2007.03.017.
[0044] Ostergaard M, Stoltenberg M, L0vgreen-Nielsen P, Volck B, Jensen CH, Lorenzen I. Magnetic resonance imaging-determined synovial membrane and joint effusion volumes in rheumatoid arthritis and osteoarthritis: Comparison with the macroscopic and microscopic appearance of the synovium. Arthritis Rheum 1997;40:1856-67. https: / / doi.Org / 10.1002 / art.1780401020.
[0045] Perry TA, Deng Y, Hulley P, Maciewicz RA, Mitchelmore J, Perry D, et al. Supportive Evidence For The Potential For Novel Biodiscovery In Osteoarthritis Through The Stepup Oa Consortium. Osteoarthritis Cartilage 2023;31 :S353-4. https: / / doi.Org / 10.1016 / J.JOCA.2023.01.393.
[0046] Daghestani HN, Kraus VB. Inflammatory biomarkers in osteoarthritis. Osteoarthritis Cartilage 2015;23: 1890-6. https: / / d0i.0rg / l 0.1016 / j.joca.2015.02.009.
[0047] Kraus VB, Collins JE, Hargrove D, Losina E, Nevitt M, Katz JN, et al. Predictive validity of biochemical biomarkers in knee osteoarthritis: Data from the FNIH OA Biomarkers Consortium. Ann Rheum Dis 2017;76:186-95. https: / / doi.org / 10.1136 / annrheumdis- 2016-209252.
[0048] Schelbergen RF, van Dalen S, ter Huurne M, Roth J, Vogl T, Noel D, et al. Treatmentefficacy of adipose-derived stem cells in experimental osteoarthritis is driven by high synovial activation and reflected by S100A8 / A9 serum levels. Osteoarthritis Cartilage 2014;22:1158-66. https: / / doi.Org / 10.1016 / j.joca.2014.05.022.
[0049] Meulenbelt I, Kloppenburg M, Kroon HM, Houwing-Duistermaat JJ, Garnero P, Hellio- Le Graverand MP, et al. Clusters of biochemical markers are associated with radiographic subtypes of osteoarthritis (OA) in subject with familial OA at multiple sites. The GARP study. Osteoarthritis Cartilage 2007;15:379-85. https: / / doi.Org / 10.1016 / j.joca.2006.09.007.
[0050] Popa C, Netea MG, Van Riel PLCM, Van Der Meer JWM, Stalenhoef AFH. The role of TNF-a in chronic inflammatory conditions, intermediary metabolism, and cardiovascular risk. J Lipid Res 2007;48:751-2. https: / / doi.org / 10.1194 / jlr.R600021-JLR200.
[0051] Berk M, Williams LJ, Jacka FN, O’Neil A, Pasco JA, Moylan S, et al. So depression is an inflammatory disease, but where does the inflammation come from? BMC Med 2013; 11 . https: / / doi.Org / 10.1186 / 1741 -7015- 11 -200.
[0052] Lambrecht BN, Hammad H, Fahy J V. The Cytokines of Asthma. Immunity 2019;50:975-91. https: / / doi.Org / 10.1016 / j.immuni.2019.03.018.
[0053] Yang Y, He X, Zhao R, Guo W, Zhu M, et al. Serum IFN-y levels predict the therapeutic effect of mesenchymal stem cell transplantation in active rheumatoid arthritis. J Trans Med 2018; 16: 165. https: / / doi.Org / 10.1186 / S12967-018-1541 -4.
[0054] Robb K, Audet J, Gandhi R, Viswanathan S. Potent mesenchymal stromal cells with desired attributes can be identified using statistical evaluation of putative critical quality attributes. June 15, 2022. Poster Presentation. Toronto Biomedical Engineering Conference (ToBE). Toronto.
[0055] Robb KP, Audet J, Gandhi R, Viswanathan S. Putative critical quality attribute matrix identifies mesenchymal stromal cells with potent immunomodulatory and angiogenic “fitness” ranges in response to culture process parameters. Front Immunol 2022; 13. https: / / doi.org / 10.3389 / fimmu.2022.972095.
[0056] Copp G, Robb KP, Viswanathan S, Culture-expanded mesenchymal stromal cell therapy: does it work in knee osteoarthritis? A pathway to clinical success. CM I, 2023. doi: 10.1038 / S41423-023-01020-1.
[0057] Dejica VM, Mort JS, Laverty S, Antoniou J, Zukor DJ, Tanzer M, Poole AR. Increased type II collagen cleavage by cathepsin K and collagenase activities with aging and osteoarthritis in human articular cartilage. Arthritis Res Ther. 2012;14(3):R113. doi: 10.1186 / ar3839.
Claims
CLAIMS:
1. A method of selecting a subject with knee osteoarthritis for a cell-based antiinflammatory treatment comprising: a) determining a test profile comprising: i. a patient-reported outcome measure (PROM) score from an assessment of knee osteoarthritis and / or a physical activity assessment from the subject; ii. a local molecular endotype feature from a synovial fluid sample from the subject, wherein the local molecular endotype feature comprises expression profiles of hepatocyte growth factor (HGF), vascular endothelial growth factor A (VEGFA), and chemokine C-C motif ligand 2 (CCL2); and iii. a systemic molecular endotype feature from a sample of serum, plasma, and / or urine from the subject, wherein the systemic molecular endotype feature comprises expression profiles of C- telopeptide of type II collagen (CTX-II) and C-reactive protein (CRP); b) comparing the values of a) with a control profile comprising (i) the PROM score from the assessment of knee osteoarthritis and / or the physical activity assessment of known responders (KRs) or known non-responders (KNRs) to the cellbased anti-inflammatory treatment, (ii) the local molecular endotype feature from the synovial fluid sample of KRs or KNRs to the cell-based anti-inflammatory treatment, and (iii) the systemic molecular endotype feature from the sample of serum, plasma, and / or urine of KRs or KNRs to the cell-based anti-inflammatory treatment; c) determining the level of similarity of a) and b); and d) selecting the subject for the cell-based anti-inflammatory treatment if there is a high level of similarity of a) to KRs; and / or a low level of similarity of a) to KNRs, and not selecting the subject for the cell-based anti-inflammatory treatment if there is a low level of similarity of a) to KRs; and / or a high level of similarity of a) to KNRs.
2. The method of claim 1 , wherein the control profile of KRs or KNRs to the cellbased anti-inflammatory treatment is first obtained by:I) determining a reference profile of one or more reference subjects with knee osteoarthritis pre cell-based anti-inflammatory treatment, comprising (i) the assessment of knee osteoarthritis and / or the physical activity assessment, (ii) the local molecular endotype feature from the synovial fluid sample from the reference subject, and (iii) the systemic molecular endotype feature from the sample of serum, plasma, and / or urine from the reference subject, wherein the local molecular endotype feature comprises expression profiles of HGF, VEGFA, and CCL2 and wherein the systemic molecular endotype feature comprises expression profiles of CTX-II and CRP;II) determining the assessment of knee osteoarthritis and / or the physical activity assessment of the reference subject post cell-based anti-inflammatory treatment;III) comparing the assessment of knee osteoarthritis and / or the physical activity assessment pre-treatment to the assessment of knee osteoarthritis and / or the physical activity assessment post-treatment in the reference subject;IV) assigning the reference subject to a KR group when the assessment of knee osteoarthritis and / or the physical activity assessment improved post-treatment compared to pre-treatment, and / or assigning the reference subject to a KNR group when the assessment of knee osteoarthritis and / or the physical activity assessment remained the same or worsened post-treatment compared to pre-treatment;V) obtaining the control profile of KRs from the reference profiles in the KR group and / or obtaining the control profile of KNRs from the reference profiles in the KNR group.
3. The method of claim 2, wherein step II) is performed 3, 6, 12, or24 months post cell-based anti-inflammatory treatment.
4. The method of claim 3, wherein step II) is performed 12 or 24 months post cellbased anti-inflammatory treatment.
5. The method of any one of claims 1 to 4, wherein determining the high level of similarity is indicated by a high correlation value computed between the test profile and the control profile, optionally wherein the correlation value is a correlation coefficient.
6. The method of any one of claims 1 to 5, wherein determining the low level of similarity is indicated by a low correlation value computed between the test profile and the control profile, optionally wherein the correlation value is a correlation coefficient.
7. The method of claim 5 or 6, wherein the correlation coefficient is a linear coefficient, optionally a Pearson correlation coefficient, or a monotonic coefficient, optionally a Spearman’s correlation coefficient.
8. The method of claim 7, wherein the high level of similarity is indicated by a Pearson correlation coefficient or a Spearman’s correlation coefficient between the test profile and the control profile having an absolute value between 0.5 to 1 , optionally between 0.75 to 1 , and wherein the low level of similarity is indicated by a Pearson correlation coefficient or a Spearman’s correlation coefficient between the test profile and the control profile having an absolute value between 0 to 0.5, optionally between 0 to 0.25.
9. Use of a cell-based anti-inflammatory treatment for treating knee osteoarthritis in a subject that has been previously identified as having a responder profile, wherein the responder profile has been identified by determining a similarity of a) a test profile comprising (i) a patient-reported outcome measure (PROM) score from an assessment of knee osteoarthritis and / or a physical activity assessment, (ii) a local molecular endotype feature from a synovial fluid sample from the subject, wherein the local molecular endotype feature comprises expression profiles of hepatocyte growth factor (HGF), vascular endothelial growth factor A (VEGFA), and chemokine C-C motif ligand 2 (CCL2), and (iii) a systemic molecular endotype feature from a sample of serum, plasma, and / or urine from the subject, wherein the systemic molecular endotype feature comprisesexpression profiles of C-telopeptide of type II collagen (CTX-II) and C- reactive protein (CRP); and b) a control profile comprising (i) the PROM score from the assessment of knee osteoarthritis and / or a physical activity assessment of known responders (KRs) to the cell-based anti-inflammatory treatment, (ii) the local molecular endotype feature from the synovial fluid sample of KRs to the cell-based anti-inflammatory treatment, and (iii) the systemic molecular endotype feature from the sample of serum, plasma, and / or urine of KRs to the cell-based anti-inflammatory treatment.
10. Use of a cell-based anti-inflammatory treatment in the manufacture of a medicament for treating knee osteoarthritis in a subject that has been previously identified as having a responder profile, wherein the responder profile has been identified by determining a similarity of a) a test profile comprising (i) a patient-reported outcome measure (PROM) score from an assessment of knee osteoarthritis and / or a physical activity assessment, (ii) a local molecular endotype feature from a synovial fluid sample from the subject, wherein the local molecular endotype feature comprises expression profiles of hepatocyte growth factor (HGF), vascular endothelial growth factor A (VEGFA), and chemokine C-C motif ligand 2 (CCL2), and (iii) a systemic molecular endotype feature from a sample of serum, plasma, and / or urine from the subject, wherein the systemic molecular endotype feature comprises expression profiles of C-telopeptide of type II collagen (CTX-II) and C- reactive protein (CRP); and b) a control profile comprising (i) the PROM score from the assessment of knee osteoarthritis and / or a physical activity assessment of known responders (KRs) to the cell-based anti-inflammatory treatment, (ii) the local molecular endotype feature from the synovial fluid sample of KRs to the cell-based anti-inflammatory treatment, and (iii) the systemic molecular endotype feature from the sample of serum, plasma, and / or urine of KRs to the cell-based anti-inflammatory treatment.11 . Use of a cell-based anti-inflammatory treatment for treating knee osteoarthritis in a subject that has been previously identified as having a responder profile by a method as defined in any one of claims 1 to 8.
12. Use of a cell-based anti-inflammatory treatment in the manufacture of a medicament for treating knee osteoarthritis in a subject that has been previously identified as having a responder profile by a method as defined in any one of claims 1 to 8.
13. A cell-based anti-inflammatory treatment for use in treating knee osteoarthritis in a subject that has been previously identified as having a responder profile, wherein the responder profile has been identified by determining a similarity of a) a test profile comprising (i) a patient-reported outcome measure (PROM) score from an assessment of knee osteoarthritis and / or a physical activity assessment, (ii) a local molecular endotype feature from a synovial fluid sample from the subject, wherein the local molecular endotype feature comprises expression profiles of hepatocyte growth factor (HGF), vascular endothelial growth factor A (VEGFA), and chemokine C-C motif ligand 2 (CCL2), and (iii) a systemic molecular endotype feature from a sample of serum, plasma, and / or urine from the subject, wherein the systemic molecular endotype feature comprises expression profiles of C-telopeptide of type II collagen (CTX-II) and C- reactive protein (CRP); and b) a control profile comprising (i) the PROM score from the assessment of knee osteoarthritis and / or a physical activity assessment of known responders (KRs) to the cell-based anti-inflammatory treatment, (ii) the local molecular endotype feature from the synovial fluid sample of KRs to the cell-based anti-inflammatory treatment, and (iii) the systemic molecular endotype feature from the sample of serum, plasma, and / or urine of KRs to the cell-based anti-inflammatory treatment.
14. A cell-based anti-inflammatory treatment for use in treating knee osteoarthritis in a subject that has been previously identified as having a responder profile by a method as defined in any one of claims 1 to 8.
15. The method of any one of claims 1-8, the use of any one of claims 9 to 12, or the cell-based anti-inflammatory treatment for use of claim 13 or 14, wherein the expression profile of CTX-II is from urine and / or the expression profile of CRP is from serum.
16. The method of any one of claims 1-8 and 15, the use of any one of claims 9 to12 and 15, or the cell-based anti-inflammatory treatment for use of any one of claims13 to 15, wherein the systemic molecular endotype feature further comprises an expression profile of interleukin 6 (IL-6) and / or cartilage oligomeric matrix protein (COMP).
17. The method, the use, or the cell-based anti-inflammatory treatment for use of claim 16, wherein the expression profile of IL-6 and / or COMP is from plasma.
18. The method of any one of claims 1 -8 and 15-17, the use of any one of claims 9 to 12 and 15 to 17, or the cell-based anti-inflammatory treatment for use of any one of claims 13 to 17, wherein the local molecular endotype feature further comprises an expression profile of resistin and / or TIMP metallopeptidase inhibitor 1 (TIMP1), and / or wherein the systemic molecular endotype feature further comprises an expression profile of tumor necrosis factor alpha (TNFa) and / or C1 -2C collagen type I and II cleavage (C1-2C).
19. The method, the use, or the cell-based anti-inflammatory treatment for use of claim 18, wherein the expression profile of TNFa is from plasma and / or the expression profile of C1-2C is from serum.
20. The method, the use, or the cell-based anti-inflammatory treatment for use of claim 18 or 19, wherein the local molecular endotype feature further comprises anexpression profile of soluble CD163 (sCD163), and / or wherein the systemic molecular endotype feature further comprises S100A8 / A9 heterodimer (S100A8 / A9).
21. The method, the use, or the cell-based anti-inflammatory treatment for use of claim 20, wherein the expression profile of S100A8 / A9 is from serum.
22. The method, the use, or the cell-based anti-inflammatory treatment for use of claim 20 or 21 , wherein the local molecular endotype feature further comprises an expression profile of adipsin and / or matrix metalloproteinase 13 (MM P-13).
23. The method of any one of claims 1 to 8 and 15 to 22, the use of any one of claims 9 to 12 and 15 to 22, or the cell-based anti-inflammatory treatment for use of any one of claims 13 to 22, wherein the cell-based anti-inflammatory treatment comprises mesenchymal stromal or stem cells, bone marrow aspirate, bone marrow aspirate concentrate, autologous fat transfer, concentrated adipose tissue, stromal vascular fraction, platelet-rich plasma, particulate or tissue derived from the placenta and / or amniotic membrane, autologous protein solution, or autologous conditioned serum.
24. The method, the use, or the cell-based anti-inflammatory treatment for use of claim 23, wherein the cell-based anti-inflammatory treatment comprises the mesenchymal stromal cells.
25. The method of any one of claims 1 to 8 and 15 to 24, the use of any one of claims 9 to 12 and 15 to 24, or the cell-based anti-inflammatory treatment for use of any one of claims 13 to 24, wherein the synovial fluid sample and / or the sample of serum, plasma, and / or urine was obtained between one month prior to and immediately prior to the cell-based anti-inflammatory treatment.
26. The method of any one of claims 1 to 8 and 15 to 25, the use of any one of claims 9 to 12 and 15 to 25, or the cell-based anti-inflammatory treatment for use of any one of claims 13 to 25, wherein the subject is a human subject.
27. The method of any one of claims 1 to 8 and 15 to 26, the use of any one of claims 9 to 12 and 15 to 26, or the cell-based anti-inflammatory treatment for use of any one of claims 13 to 26, wherein the subject has not received a previous treatment for knee osteoarthritis.
28. The method of any one of claims 1 to 8 and 15-26, the use of any one of claims 9 to 12 and 15 to 16, or the cell-based anti-inflammatory treatment for use of any one of claims 13 to 26, wherein the subject has previously received at least one treatment for knee osteoarthritis.
29. The method of any one of claims 1 to 8 and 15 to 28, the use of any one of claims 9 to 12 and 15 to 28, or the cell-based anti-inflammatory treatment for use of any one of claims 13 to 28, wherein the assessment of knee osteoarthritis comprises Knee injury and Osteoarthritis Outcome Score (KOOS), Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), Visual Analogue Scale (VAS), Short Form 36 (SF-36) or Short Form 12 (SF-12), Tegner Lysholm Knee Score, Knee Society Clinical Rating System, Lequesne Index for Knee Osteoarthritis, Oxford Knee Score (OKS) and / or International Knee Documentation Committee (IKDC) Questionnaire.
30. The method, the use, or the cell-based anti-inflammatory treatment for use of claim 29, wherein when the assessment of knee osteoarthritis comprises KOOS, the PROM score comprises Function in Sports and Recreation (Sports / Rec) and / or Overall KOOS.
31. The method, the use, or the cell-based anti-inflammatory treatment for use of claim 29 or 30, wherein when the assessment of knee osteoarthritis comprises WOMAC, the PROM score comprises Overall WOMAC.
32. The method of any one of claims 1 to 8 and 15 to 31 , the use of any one of claims 9 to 12 and 15 to 31 , or the cell-based anti-inflammatory treatment for use of any one of claims 13 to 31 , wherein the physical activity assessment comprises Marx Activity Rating Scale (MARS), SF36 Physical Function Score, International PhysicalActivity Questionnaire (IPAQ), Timed Up and Go Test (TUG), and / or 6 Minute Walk Test.
Citation Information
Patent Citations
Companion methods and kits for il-2-based therapies and mesenchymal stem cell-based therapies
WO2016196765A2
Methods and devices for the production and delivery of beneficial factors from stem cells
WO2016196774A1
